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Abstract
With the rapid advancement of computational data analysis tools, medical informatics has
emerged as a discipline that explores the use of medical information in clinical practice. It
searches for ways to effectively integrate as much information as is available to physicians
when they make clinical decisions and represent the information in the most intelligent way
possible.
As part of an overall effort to develop a program that assists physicians in making
clinical decisions on patients with heart disease, we developed a model for predicting therapy
effects in heart disease using signal flow analysis that describes constraint relations among
physiological parameters. In order to accurately describe and predict the therapy effects on
a patient in heart failure, the model needs to be tested and analyzed with real-life patient
data including any cardiovascular parameters measurable in the patient. This thesis will
present methods for extracting hemodynamic relations and drug effects from patients in
the intensive care unit. In this thesis, we propose to test our hypothesis that significant
relationships between hemodynamic parameters can be derived from certain classifications
of patients and sectioning of hospital stays, and explore the effects of drugs on patients with
different sets of diseases.
Thesis Supervisor: William J. Long
Principal Research Associate at the CSAIL Laboratory
Title: Thesis Supervisor
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Chapter 1
Introduction
With ongoing rapid advancements in computational data analysis tools and communica-
tion technology, it has become easier than ever to organize, share, and analyze health care
information. Medical informatics is an emerging field that explores the ways to effectively
integrate as much information as is available to physicians when they make clinical deci-
sions, and represent the information in the most intelligent way possible. Research in this
discipline is often misunderstood to focus on information content, while the emphasis is
actually on the algorithms used to manipulate the information. The ultimate goal is to uti-
lize the data that is available to design and develop decision-support systems in healthcare
services that would improve the quality of patient care.
The pace at which research fosters new ideas has made it impossible for practitioners to
keep up, even when needed, with the most current information in the field when treating a
patient. In addition, advances in medical instrumentation further complicate the decision
process by giving practitioners an overload of detailed hemodynamic parameters. It can
become overwhelming sometimes to learn such vast amounts of information in a short time,
just in time to make clinical decisions. This thesis is part of an overall effort to develop a
system that improves the quality of patient care through helping practitioners in managing
patients in heart failure, including alarm systems, disease diagnosis, and therapy application.
As the heart of human physiology, the cardiovascular system consists of numerous com-
plex interacting physiological mechanisms that respond to interventions. The system's state
can be defined as the snapshot of cardiovascular parameters at a moment in time. These
interventions range from changes in mental state, drug applications, fluids, to exercise.
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Therapy effects could differ among patients and even within the same patient depending
on the physiological state the patient is in. Effectively treating patients in heart disease
requires experience, thorough understanding of both patient-dependent and -independent
interrelations in cardiovascular physiology, and the ability to make intelligent and informed
decisions among the different methods of therapy.
To assist the practitioners in such circumstances, specifically, to predict a patient's
response to therapy, we have developed a model based on signal flow analysis that describes
the relations among cardiovascular parameters in a linear model. Our goal is to use patient-
specific information and documented knowledge about cardiovascular drugs and their effects,
to verify the correctness of the signal-flow based model on the cardiovascular system. We
use real-life patient data to do a case-breakdown analysis of how well our model simulates
the processes of the cardiovascular system at the time of intervention. The results will
determine if the model accounts for the changes that take place in a patient state between
two points in time, and show if the model is over-constrained or under-constrained. This
will be useful to practitioners in understanding how patients differ from one another and
how they would react to treatments.
Many complications arise when extracting relevant data from the patient database that
can be used for testing constraint relations in the model. These complications include, but
are not limited to, identifying regions during the patient's hospital stay where there is only
one varying parameter, and categorizing patients to minimize differences in physiological
states among patients from the same group. Different patients react differently to the same
stimulus because of their differing physiological state, defined by the diseases they have, or
had, and several other factors. Our hope is to find similarities among patients that can be
used as the norm when predicting therapy effects. We will present methods on extracting
statistically significant relationships between measurable hemodynamic parameters among
the various types of patients in and out of intensive care units (ICU), to see how well they
correspond to the ones in the model.
The rest of this chapter will go over the model that we will be testing and the data
used for performing the analysis. In Chapter 2, we will describe our approach in extracting
relationships between hemodynamic parameters during steady states and times of interven-
tion in various patients. Chapter 3 and 4 will present the raw results, and discuss why the
results are the way they are and how they compare to the model, respectively.
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1.1 Background
Section 1.1.1 will give a brief description on the model that we will be analyzing and what
advantages it has over other cardiovascular models and the algorithm involved. Section
1.1.2 talks about the dataset that we will be using for the analysis.
1.1.1 Cardiovascular Model Based on Signal Flow Analysis
Cardiovascular models cover a great range, from models for specific purposes like the pul-
satile model on cardiac electrotherapy [21], to Guyton's general purpose cardiovascular
model [6]. These models encompass a variety of modeling methods, including numeric and
qualitative simulations, on the cardiovascular system to simulate responses to interventions.
A majority of them relates to Guyton's idea that it is not the heart itself, but peripheral
circulation that defines the cardiac output (CO). The cardiovascular simulation developed
by Guyton itself, is an example of numeric simulation that runs from a set of initialized
parameters to another set of parameters whose values correspond to the desired change [6].
Simulations generate a sequence of successive states leading to the desired change in the
parameters. Outputs of these simulations, however, do not convey the path of cause and
effect links that produced such responses to the intervention, nor does it provide for the
variations in physiology between patients due to the limited set of variables.
Qualitative simulations, on the other hand, allow a higher abstraction of the actual
mechanisms of cardiovascular physiology. In another words, simulations using the method-
ology are constructed from how physicians reason about physiological relations, and not on
the actual physical mechanisms that are involved [11].
The therapy prediction model developed by Long [13] addresses the aforementioned
problems, namely, how to preserve path and allow flexibility in simulating human physiol-
ogy. Using a signal flow analysis algorithm on a set of constraint-based relations between
hemodynamic parameters, the model is able to preserve the paths through which therapy
changes each parameter. Path preservation gives practitioners the option of looking at which
path has the biggest contribution to the change (total change to a parameter is calculated
by adding up all the gains through that parameter).
Figure 1-1 shows the relations between top-level hemodynamic parameters in the therapy
prediction model. Both linear and non-linear relations are used for capturing the physiology
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Figure 1-1: Therapy prediction model. RV=right ventricular output, PAP=pulmonary artery pres-
sure, LAP=left atrial pressure, RVE=right ventricular emptying, PVR=pulmonary vascular resistance,
RVC=right ventricular compliance, RVSF=right ventricular systolic function, PV=pulmonary volume,
RVD=right ventricular dysfunction, IS=inotropic state, RVR=right ventricular resistance, RAP=right atrial
pressure, LVD=left ventricular dysfunction, LVSF=left ventricular systolic function, LVC=left ventricular
compliance, HR=heart rate, VC=ventricular constant, LVE=left ventricular emptying, CO=cardiac output,
VV=venous volume, SS=sympathetic stimulation, SVR=systemic vascular resistance, VS=vagal stimula-
tion, BV=blood volume, MAP=mean arterial pressure
of the cardiovascular system. To generate a system of linear equations, the simulations runs
on a set of linear equations by approximating non-linear relations using piece-wise linear
ones. Equations 1.1 through 1.3 is a snapshot of a subset of the constraints used in the
model.
Constraint relations among hemodynamic parameters are obtained from physiology and
medical literature. The qualitative nature of the model allows the relations to be reasoned
in a more intuitive way from steady state to steady state. Even though therapy effects
evolve over time, the model takes a different approach in reaching the same goal; changes
to parameters are calculated from steady state to steady state. In steady state, CO is equal
to venous return (Figure 1-2).
A lot of testing has already been done using cases obtained from literature. A summary
of results from previous simulations' is shown in Tables 1.1 through 1.4. These results show
'Summary of comparisons obtained from [13]
20
lungs . blood returning
from the lungs to
the heart
atrium atrium
right AV left AV
pulmonary valve +-- o aortic valve
ventricle ventricle
capillaries
blood retuming to heart blood going to body
from body (venous retum) (cardiac output)
Figure 1-2: Blood flow in the pulmonary circuit.
that therapy effects have the same direction of change in real data and model simulations
for propranolol and nitroglycerin, with a small discrepancy on hydralazine where left atrial
pressure (LAP) changed in different directions for actual and predicted values.
The model, however, does not predict the exact values; there is usually a small difference
between actual and predicted values. In addition, these cases are restricted to patients who
have a limited number of varying parameters (e.g. there is only one disease among all
patients in a sample space), which are in no way representative of the kinds of patients
admitted to ICU. Whatever results we obtain under these circumstances will not be useful
in a real ICU setting. With the introduction of computerized monitoring systems in ICUs
and continuous efforts in developing de-identification policies and methods, only recently
were we able to get access to thousands of patient medical records (described in further
detail in the next section), which has become a useful resource in allowing us to perform a
more comprehensive testing on the therapy prediction model.
1.1.2 Patient Medical Records
One of the most essential steps in developing any model is running simulations of situations
that might happen in real life. For our purpose, we start from the other end, by com-
paring any significant statistical relationships between hemodynamic parameters in patient
medical records to what we have defined in the model. We obtain these medical records
from the Multi-parameter Intelligent Monitoring for Intensive Care II (MIMIC II) database
21
rest A 83 5.7 88 23 9 32
exercise A 130 8.0 113 39 9 55
P 127 8.0 112 42 9 58
rest A 95 5.9 93 22 9 32
propranolol A 82 4.8 91 18 11 29
P 82 4.8 92 21 12 31
propranolol A 104 6.4 95 30 10 46
+ exercise P 108 6.4 98 29 12 45
Table 1.1: Actual and predicted parameters in mitral stenosis with propranolol and exercise.
A= actual values, P= predicted values, BP= blood pressure, EDP= left ventricular end diastolic pressure
state HR ICO BP LAP EDP
rest A 79 4.5 94 27 12
exercise A 116 6.3 111 43 13
P 121 6.3 109 47 12
rest A 82 5.2 91 27 11
nitroglycerin A 87 4.6 85 21 8
P 93 4.6 85 22 8
nitroglycerin A 113 5.9 102 37 10
+ exercise P 122 5.9 99 34 9
Table 1.2: Actual and predicted parameters in mitral stenosis with nitroglycerin and exer-
cise.
state HR CO LVSP BP LAP PAP
rest A 95 7.6 114 83 9 16
exercise A 151 13.4 136 88 10 19
P 154 13.4 139 89 9 18
Table 1.3: Actual and predicted parameters in aortic stenosis in children with exercise.
LVSP= left ventricular systolic pressure
state HR ICO ILVSP BP LAP PAP RAP
control A 82 3.8 110 93 27 39 11
hydralazine A 85 5.7 - 88 25 36 11
P 102 5.3 108 83 28 38 11
I 94 5.7 120 87 26 38 10
Table 1.4: Actual and predicted parameters in aortic stenosis with hydralazine. 1= predictions
assuming an inotropic effect for hydralazine
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state HR CO BP LAP EDP PAP
BP = (CO * SVR) + RAP (1.1)
CO = LVOUTPUT - AR-FLOW - MR-FLOW (1.2)
LAP = if (PV < 0.7)
then((36.0 * PV) - 10.2)
else((125.0 * PV) - 72.6) (1.3)
(1.4)
Figure 1-3: Constraints in the therapy prediction model. BP=blood pressure, CO=cardiac
output, SVR=systemic vascular resistance, RAP=right atrial pressure, LVOUTPUT=left ventricular out-
put, AR-FLOW=aortic regurgitation flow, MR-FLOW=mitral regurgitation flow, LAP=left atrial pressure,
PV=pulmonary volume
developed by the MIT Laboratory for Computational Physiology (http://mimic.mit.edu).
The database is in continuous development with an increasing number of patient medical
records collected from ICU patients at the Beth Israel Deaconess Medical Center.
Figure 1-4 shows how the data is being collected in the ICU and what is involved2
Ongoing advances in medical instrumentation in the ICU provides a plethora of in-
struments capable of taking extremely detailed data on hemodynamic parameters, such as
blood pressure (BP) and heart rate (HR), recorded and stored in a database. MIMIC II
is being built for the purpose of storing and organizing this data in the most logical way
to support research in intelligent patient monitoring systems used for collaborating and
interpreting data. Besides the hemodynamic parameters and drug application, the kind
of information contained in the database ranges from events of dressing change, discharge
summaries, to Internal Classification of Diseases (ICD9) codes for diseases attributed to
each patient. Currently the database contains over 17,000 patient medical records with
entries in the ICD9 code table. Each entry of a physiological parameter is averaged over
a half-an-hour period, with possible delays until the next entry. There are other forms of
data, such as waveforms, that we chose not to use because the averaged values are more
suitable for the model. Information on the dose, time, and type of each intravenous drug
given to patients are also recorded in the same way.
MIMIC II is built as a relational database, keyed by unique Patient Identification num-
bers for easy access and efficient data collaboration. Knowledge of the unique patient ID is
enough to collect all the de-identified information available on that patient in the database.
2 From [17]
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Figure 1-4: MIMIC II data architecture.
Being able to access data using table relations works in our favor, as many times we want
to extract a list of patients having taken a particular drug like dobutamine, or exhibiting
a certain type of disease, which is only possible with the recent inclusion of a ICD9 code
table.
We will mostly be using three tables from the database: MedEvents, ChartEvents, and
ICD9. Below is a list of descriptions for each table and the columns that will be useful for
our purpose.
" ChartEvents: charted events, including hemodynamic parameters and dressing change
- itemid: unique itemid assigned to each type of chart event
- pid: patient identification number
- chartTime: time of event
- valuel: measurement
- value2: measurement (used for parameters such as BP that have two values, e.g.
systolic and diastolic)
- stopped: flag indicating whether the event is stopped at this chartTime
" MedEvents: intravenous (IV) medications
- itemid: unique itemid assigned to each drug
- pid: patient identification number
- chartTime: time of drug application
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- dose: amount of dosage applied
- stopped: flag indicating whether the drug is stopped at this chartTime
e ICD9: Internal Classification of Disease codes for all diseases in the database
- pid: patient identification number
- diag-dot-cd: ICD9 code in dot form
The medEvents table only covers IV drugs with drugs taken by mouth recorded only in
the nursing notes. The only way to extract data from the free text of the nursing notes
is using natural language processing methods to obtain information on the dose and time
of such drug applications. Often the time of application is actually not recorded for oral
drugs. Given that we extracted the specifics of a drug dose from the nursing notes, it is
still very probable that the nursing notes do not have the time of drug application. In that
case, the time would have to be inferred through other methods such as clinical judgment.
Extracting time and dose of oral drugs using natural language processing or other methods
will not be covered here. Instead, we will make the assumption that the hemodynamically
important drugs are intravenous, given that we are dealing with ICU patients. However,
the fact that the same patients might be simultaneously taking other oral drugs that affect
BP, HR, etc. cannot be completely ruled out.
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Chapter 2
Methods
Only a limited number of hemodynamic parameters can be measured in a patient without
being overly intrusive. Both BP and HR can be measured non-invasively. Parameters such
as inotropic state indicating the contractility of the heart, however, cannot be measured
directly. Measurements of CO usually require invasive methods of cardiac catheterization.
In this thesis, we will be looking at how changes in a hemodynamic parameter and drug
interventions affect other parameters in the patient. We will present methods for analyzing
two relationships between measurable hemodynamic parameters that can be found in most
patients during steady state. Specifically, how does a change in BP affects HR, and LAP
on CO? Relations A and B in Figure 1-1 reflect these two relations we will be examining
in the therapy prediction model. And in what way does a beta-blocker, vasoconstrictor, or
inotropic agent change a patient's physiological state?
The next section presents two consistency checkers imposed on the raw data before it
is used in the analysis. Sections 2.2 and 2.3 will look at how to use state-based classifica-
tion methods on a patient's hospital stay, to obtain the correlation coefficients for the two
relationships we are examining, BP -+ HR, and LAP -+ CO. Then Section 2.4 presents
multi-segment linear regression as another method for refining the initial data classification
for finding hemodynamic relations. Lastly, Section 2.5 will cover the methods used for
measuring how well a patient's response to interventions correspond to research in the field
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2.1 Consistency Checks
There always exist discrepancies in biological data due to instrumentation or human error,
or simply programming error when data is transferred into a computer system. In an
attempt to get as clean a data set as possible, we identified methods to smooth the curves
for each hemodynamic parameter before they are used in any calculations. The next two
sections describe how we filtered values for BP and LAP in situations that are inconsistent.
2.1.1 Mean Blood Pressure
Values for mean arterial blood pressure (MAP), which we use as our BP values, entered
in MIMIC II are calculated from a moving average of diastolic (DBP) and systolic blood
pressures (SBP), which are measured directly in the patient. The system uses a validity
checker for both DBPs and SBPs to throw out data points before storing them in MIMIC II.
However, it uses a different validity checker for MAP values when they are calculated from
the raw DBP and SBP values. In other words, raw data points thrown out for smoothing
the DBP and SBP curves might actually be used in calculating the moving average for MAP.
Differences between the two validity checkers create inconsistencies between DBP/SBP and
MAP.
Even though the validity checker for MAP might be correctly filtering out noise, it is
impossible to determine which of the two checkers is correct, or if both are wrong. If there
exists an inconsistency, it is also an indication that the two checkers do not agree on how to
label the current entry due to noisy data. Therefore, we use another consistency checker to
determine whether or not to keep the data point; a MAP and its corresponding DBP and
SBP with the same time of entry must satisfy both of the two equations below.
DBP < MAP < SBP
SBP > DBP
The two equations actually imposes a quite loose restriction on the relationship between
MAP and DBP/SBP. Stricter requirements could be implemented quite easily, but at the
same time, there would be a loss of data points available for analysis.
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2.1.2 Left Atrial Pressure
Left atrial pressure is seldom measured in a patient, for the same reason the left ventricu-
lar pressure measurement is usually absent from nursing notes - they both require cardiac
catheterization, often intraoperatively. The importance of LAP in diagnosing mitral valve
disorders, however, have prompted many to devise methods to indirectly measure the pa-
rameter. Pulmonary capillary wedge pressure (PCWP) is an indirect measurement of LAP.
Although there is still continuing controversy on the accuracy of this estimation, it is still
widely used for clinical purposes, nevertheless. We will also be using PCWP to make up
for the lack of measurements on LAP in MIMIC II. Pulmonary arterial diastolic pressure
(PAPD) will also be used as an estimation for LAP, in addition to PCWP. PAPD and
LAP should only differ when there is pulmonary hypertension that creates resistance in the
lungs'.
With the addition of PAPD, we are able to perform consistency checks on the estimated
LAP. First of all, the diastolic pressure is often complemented with a systolic pressure
(PAPS) and a mean pressure (mPAP). Secondly, since both PCWP and PAPD are estima-
tions of LAP, the two parameters should be roughly equal, if not exactly. Any PCWP/PAPD
measurements that do not satisfy the following equations are basically excluded from any
calculations.
PAPD < mPAP < PAPS
PAPS > PAPD
IPAPD - PCWP < 5 (2.1)
2.2 Classification of Blood Pressure Time Segments Based
on a Breakdown Analysis on Patient States
Just as everyone appears physically different, even twins, human physiology differs between
individuals. An individual's physiological state is determined by many factors, including the
inherent differences between people, diseases, sudden change in mental state or emotions
[18], drug application, and even change in position.
'Refer to Section 2.3.1
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Here, we are trying to find relationships between hemodynamic parameters when the
patient is in a stable state during which relations stay constant. During such a time period,
there should be no sources that can possibly change how one parameter affects another
parameter. In addition, drugs given to ICU patients have short term feedbacks such that
relations reach equilibrium in each of the time segments we are examining. To determine
where these time segments are located during a patient's hospital stay, we have to first
identify what makes each patient unique in terms of his response to interventions. Under-
standing the underlying mechanisms that make each patient unique is the key to obtaining
hemodynamic relations for each patient.
Heart rate responds to exercise, inactivity, pain, anger, anxiety, stress. However, patients
in MIMIC II are usually on sedatives like bnz-benzodiazepines, propofol, and neuroleptic
agents. So HR should not be affected by these factors. The other possibilities of a change in
HR is in how the heart muscle conducts electrical impulses and the amount of sympathetic
stimulation. By eliminating documented sources of change, we can find out how BP relates
to HR in the most understandable way possible.
Section 2.2.1 will focus on an initial patient classification based on disease state. In
Sections 2.2.2 and 2.2.3, classifications will be carried further in the form of time segments
in each patient based on drug types, then into ranges of therapy effects in each segment.
Lastly, Section 2.2.4 will summarize the classification methods discussed so far.
2.2.1 Disease State
There are many things that affect how a change in BP affects HR. Arrhythmia and car-
diomyopathy are the two conditions we consider as the diseases that play a major role in
disturbing the hemodynamic relations. The next two sections will discuss why and how we
are filtering them out for the analysis.
Arrhythmia
Variations of arrhythmia include slow or fast heartbeats, and paroxysmal or chronic. Atrial
fibrillation, atrial flutter, Wolff-Parkinson-White syndrome, and tachycardia are all condi-
tions having fast heart rate due to abnormal conduction of electrical impulses through the
heart muscle. A fast heart rate usually means more than 100 beats per minute. In brady-
cardia, impulses do not travel all the way to the heart's pumping chambers or travel at a
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lower speed, causing the heart to beat slower than usual at less than 60 beats per minute.
The condition can also be paroxysmal if it occurs and ends abruptly, as opposed to chronic
when irregular rhythms last until they are treated.
Although fast heart rates also occur during exercise or slow rates in physically fit or
healthy young individuals, MIMIC II includes only patients from the ICU. In other words,
if an arrhythmia is observed in a patient in observation, it is due to abnormal conduction
of electrical impulses through the heart muscle.
Our hypothesis is that for a patient with any variation of arrhythmia, it is very likely
that due to abnormal conduction paths, the heart acts on its own terms and is less con-
trolled by other sources. Therefore, non-arrhythmic patients should have better correlation
between their BPs and HRs because HR is affected by sympathetic stimulation caused by
BP changes. On the other hand, arrhythmic patients have less of a correlation between
these two hemodynamic parameters because the effects from changes of BP is overwhelmed
by the irregular rhythm caused by abnormal conduction paths.
In MIMIC II, out of the 17082 patients with entries in the ICD9 table, 3870 have chronic
atrial flutter or atrial fibrillation at some point during their hospital stay, and are classified
as 'arrhythmic', even if they do not have arrhythmic conditions for their entire hospital
stay. The rest of the patients without atrial flutter or atrial fibrillation are categorized as
'non-arrhythmic'. But in reality, a lot of these 'non-arrhythmic' patients have paroxysmal
arrhythmia, where they have short episodes of irregular heart rhythm. To consider the
possibilities of abnormal heart rhythms due to arrhythmia in non-arrhythmic patients and
normal heart rhythms in arrhythmic patients, we also distinguish between arrhythmic and
2
non-arrhythmic regions
We will use correlations to test our hypothesis that arrhythmia has a role in disturb-
ing hemodynamic relations, such that there is less of a correlation between hemodynamic
parameters in arrhythmic than in non-arrhythmic regions.
2 A region has abnormal heart rhythm if its heart rhythm value in MIMIC II is any of the following:
atrial flutter, sinus arrhythmia, second-degree AVB Mobitz 1, complete heart block, paced, supraventricular
tachycardia, ventricular fibrillation, paroxysmal atrial tachycardia, junctional, wandering atrial pacemaker,
Wenckebach, V paced, AV paced, ventricular tachycardia, asystole, A paced, idioventricular, multifocal atrial
tachycardia, second-degree AVB Mobitz 2, Zoll pacemaker, atrial fibrillation.
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Cardiomyopathy
Sympathetic stimulation is a source for changes in HR, as a function of changes in BP.
It's part of the homeostasis mechanism activated by baroreceptors to regulate BP. When
activated, the sympathetic division of the autonomic nervous system releases hormones into
the bloodstream to increase HR through sympathetic plexus, in response to decreasing BP.
The parasympathetic division of the nervous system, on the other hand, mediates increases
in BP through decreases in HR.
Besides BP and drugs (Section 2.2.2), having cardiomyopathy can also change the way
baroreceptors activate the sympathetic division. Cardiomyopathy enlarges the heart and
weakens the heart muscle, making the heart incapable of pumping enough blood to circulate
around the body. Baroreceptors has been shown to have decreased sensitivity and efficiency
in patients with dilated cardiomyopathy [14]. In other words, the patient's homeostasis
mechanism does not regulate BP through HR effectively. Distinguishing patients based on
cardiomyopathy allows us to examine hemodynamic relations with less noise due to the
different ways baroreceptors react to the same amount of change in BP in these patients.
We will make the assumption that cardiomyopathy, just like arrhythmia, has an effect
on sympathetic stimulation and combine patients with arrhythmia or cardiomyopathy into
one group, such that the other group will have neither an arrhythmia nor cardiomyopathy.
For the rest of this thesis, we will using the term 'arrhythmic' to refer to patients with either
arrhythmia or cardiomyopathy, and 'non-arrhythmic' for patients with neither arrhythmia
nor cardiomyopathy.
2.2.2 Sympathetic Stimulation from Drugs
The previous section talked about how baroreceptors activate the sympathetic nervous sys-
tem to mediate decrease in BP through HR. This coupling of baroreceptors and activation of
the sympathetic system is the natural form of BP regulation. However, biological advances
have made it possible to increase sympathetic stimulation with drugs. These drugs are
called autonomic drugs and affect the sympathetic/parasympathetic nervous systems. Ex-
amples of autonomic drugs are dobutamine/dopamine and epinephrine, and beta-blockers
propranolol and metoprolol. Beta-blockers not only correct an irregular heart beat, they
also treat hypertension through sympathetic stimulation. Many of those patients in the
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DRUG NAME FUNCTION
dobutamine/dopamine beta-blocker, reduces BP
epinephrine vasoconstrictor, heart stimulant
esmolol beta-blocker, reduces HR and BP
labetolol beta-blocker, reduces BP
neosynephrine vasoconstrictor, increases BP
milrinone increases CO and LAP
Table 2.1: Sympathetic drugs used by patients in MIMIC II.
MIMIC II database are given autonomic drugs at some point during their hospital stay.
When given autonomic drugs, the patient reacts differently to changes in BP, holding true
to the proposed effects of each particular drug. Table 2.1 is a list of autonomic drugs that
patients in MIMIC II have taken that we will take into consideration in our analysis. Com-
pared with when HR is only being mediated through the patient's homeostasis mechanisms,
these drugs may enhance or lessen the capabilities of the system to increase HR and myocar-
dial contractility. Our goal is to find relationships that can be attributed to certain groups
of patients, and certain regions of a patient's hospital stay, that describe how parameters
interact with each other. Since autonomic drugs change the way HR increases, we divide
each patient's stay into time segments of different states, such that relations in each time
segment are obtained with minimum noise.
Figure 2-1 shows how a patient's hospital stay is divided into regions depending on
what drugs he is taking in each region. Dopamine affects sympathetic stimulation, whereas
heparin does not. For this particular case, we divide the patient's hospital stay into 3 regions:
no dopanine (heparin), dopamine (dopamine with or without heparin), and no dopamine
(heparin). For the regions with heparin alone, we know that there are no sympathetic
drugs acting on the patient, and thus, any relations obtained in this time segment reflects
the patient's natural homeostasis mechanism of BP regulation. However, for regions where
the patient is also receiving dopamine, dopamine increases sympathetic stimulation and
HR. By looking at different time periods, we are trying to answer the following questions:
" What is a patient's natural physiological mechanism when there are no interventions?
" What is a patient's physiological mechanism when he is taking
a. non-autonomic drugs?
b. autonomic drugs?
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Figure 2-1: Time segments assigned to patient 1469's hospital stay using state-based clas-
sification on sympathetic regions.
Ideally, a patient should react the same way to changes in BP in both the first and the last
region with heparin. The same reasoning also applies to the two regions with both heparin
and dopamine. But a region with heparin alone is different from a region with both heparin
and dopamine. The third region with dopamine alone should also have the same relations
as the two regions before and after it. We will be testing the hypothesis mentioned above to
see if it holds true among different patients and within the same patient. Drugs identified
in this thesis as 'sympathetic' are dobutamine, dopamine, epinephrine, esmolol, labetolol,
milrinone, neosynephrine (Table 2.1).
2.2.3 Dependency of Response on Change in Blood Pressure
A patient reacts to interventions depending on what state he is in. A state could mean at
the current moment in time, the types of diseases he has been diagnosed with, the emo-
tional state he is exhibiting, and also the state of his hemodynamic parameters. The next
two sections describe the reasoning behind taking into consideration the state of BP and
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LAP for calculating relationships. Our initial hypothesis of how HR changes in response to
changes in BP from cases studied in literature (from a small set of patients) is as follows:
if ABP < 0 - AHR 1.884 * ABP
if ABP < 30.3 - AHR 1.686 * ABP
else AHR = 1.455 * ABP
In our analysis, we will also look at the different ways HR responds to BP depending
on the range of ABP. Specifically, four different hemodynamic relations are obtained from
patients: when ABP satisfies ABP<0, -10<ABP<10, 0<ABP<20, or 15<ABP<30. Since
we are uncertain on the ranges of ABP during which the relation between BP and HR is at
steady state, overlapping ranges are used to explore the possibilities, rather than contiguous
ranges.
ABP here is defined as the change in BP between two consecutive points, regardless
of the time interval. Let's say we have BP=60 at time=0, BP=62 at time=1, and BP=59
at time=5. Then we will get two values of ABP, ABP=2 for the first time interval and
ABP=-3 for the second interval.
2.2.4 Correlations on ABP and AHR with Minimal Sympathetic Stimu-
lation
To summarize the classifications described so far, in Sections 2.2.1, 2.2.2, and 2.2.3, Figure
2-2 shows how we categorize the patients and their hospital stay. The next two sections
describe the ranges of values used in further details.
patient NoHa atria] fbutr? 10ono H w mamny nautoomic rdrugs? W, How much did BP change?
Has cardiomyopathy?
Figure 2-2: Steps in classifications.
MIMIC II's ICD9 table make it possible to follow the first classification quite easily, in
whether a patient has one, both, or none of arrhythmia and cardiomyopathy. Then, along
with a list of the autonomic drugs recorded in MIMIC II, the medEvents table allows us to
classify each patient's hospital stay into 6 finer categories of combinations of autonomic and
non-autonomic drugs the patient is taking: no classification, no drugs, 1 autonomic drug, 1
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non-autonomic drug, 2 autonomic drugs, 2 non-autonomic drugs. The third step requires
us to keep only relevant entries (BP decreased, or BP increased more than 10 but less than
20, etc.) where the difference in BP from previous entry belongs to one of the ranges of
ABP mentioned in Section 2.2.3. Correlation coefficients are calculated using ABP and
AHR.
2.3 Classification of Left Atrial Pressure Time Segments Based
on a Breakdown Analysis on Patient States
As shown with relation A in Figure 1-1, there is a direct effect on CO coming from LAP. The
next section will discuss why we still have to take pulmonary hypertension into consideration
when we are classifying patients for this relationship. And Sections 2.3.2 and 2.3.3 will look
at how effects on CO is dependent on the current value of LAP and calculation of correlation
coefficients.
2.3.1 Pulmonary Hypertension
Previously discussed in Section 2.1.2, PAPD and PCWP are used as estimations for LAP
due to the lack of direct LAP measurements. However, looking closely at the pulmonary
circuit shown in Figure 1-2, the PAPD estimate holds only when the lung does not influence
the blood flow between right ventricle and left atrium. In other words, if the lung is diseased
and changes the resistance on that section of the pulmonary circuit, PAPD is no longer a
good estimate of LAP, nor is it quantitatively close to PCWP.
A lung disease that affect the PAPD estimate significantly is pulmonary hypertension,
which is the condition of high blood pressure in the pulmonary arteries that supply blood
to the lungs [19]. In fact, for patients with this condition, PAPD>>PCWP, contradicting
one of our consistency checkers for LAP in Equation 2.1.2. As a result, for the sake of
obtaining measurements on LAP using PAPD, we have excluded patients with pulmonary
hypertension since these patients compose only 3.8% of the patient data set.
2.3.2 Frank-Starling Curve on Cardiac Output and Left Atrial Pressure
Given the type and amount of dosage and a snapshot of a patient's state, A0 , the therapy
prediction model will predict the hemodynamic changes for the next steady state, called A1 .
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Let's say the model is programmed to run on a sequence of states, with the same type of
intervention on each run. The next state required for initializing the model, Aj, is the same
as Ai- 1 , where Ai_ 1 is the resulting hemodynamic changes from the previous run Ai- 2. In
other words, a patient is given a dose of the drug every time he reaches steady state. If the
sequence of states is long enough, the very last state predicted by the model will include
parameters that are NOT capped. For example, LAP can go over 100, or HR over 200, etc.
The model can only make accurate predictions before any one of the parameters go over
their theoretical limits outside the model's operating range.
Cardiac output
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Figure 2-3: Frank-Starling Law on CO and RAP.
The Frank-Starling curve suggests that the greater the ventricular end-diastolic volume,
the greater the force of contraction, which generates more stroke volume (SV). Cardiac
output is positively correlated with SV, CO = HR * SV, given that HR stays constant.
Looking at Figure 1-2, what is pumped in and out of right ventricle is also pumped in and
out of the left ventricle. Relationship between CO and LAP should be similar to that of CO
and RAP defined by the Frank-Starling law, shown in Figure 2-3, similar to Guyton's curve
on RAP and venous return [7]. Cardiac output flattens out after LAP reaches a certain
value. The plot can then be divided into two regions: a linear region where CO increases
linearly with LAP, a flat region where CO stays constant.
In obtaining the relationship between CO and LAP for the patients in MIMIC II, we
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will also be applying the Frank-Starling law to divide each patient's LAP measurements
into linear regions followed by a flat one. The ranges we will be considering are from 0 to
20, 20 to 25, 25 to 30, and over 30, so we can see if there is a linear region followed by a
flat region.
2.3.3 Correlations on Left Atrial Pressure and Cardiac Output Using
Piece-wise Linear Analysis
Factoring pulmonary hypertension into patient classification is solely for the purpose of
data accuracy, as discussed previously in Section 2.3.1. The main classification used in
calculation correlations on CO and LAP lies in the Frank-Starling relation; each patient's
LAP measurement over the whole hospital stay will be grouped as described in the previous
section. Correlations on LAP and CO are calculated independently of each other in each
group.
2.4 Classification of Time Segments Based on Multi-Segment
Linear Regression
Here we present another method for finding the boundaries for time segments in a patient's
hospital stay - multi-segment linear regression. A lack of automatic extraction of events
from nursing notes make it possible for a physiological state to change in the middle of a time
segment defined using patient states. Such events could include application of oral drugs,
changes in position and mental state, all of which we could not take into consideration for
the classification method based on patient state. The next section will look at multi-segment
linear regression and a case study will be presented in Section 2.4.2.
2.4.1 Multi-Segment Linear Regression
Together, the methods described in the previous sections are a way to divide patients and
their hospital stays into 'cleaner' regions, such that hemodynamic relations can be obtained
without disturbances from other factors. Using multi-segments regression analysis on BP
and LAP consists of another way to define the bounds of each 'clean' region.
Fitting not one, but many segments to the data, allows a patient's hospital stay to
be divided into regions that makes the most sense when calculating least squared error.
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For example, the two regions that we might have defined using the other method could be
combined into one region using multiple-line regression, if the slope is similar for the two
regions. This method gives us another prospective on the things that may change how a
patient responds to changes in BP through increasing/decreasing HR besides merely the
type of drug, or in LAP through CO; things happening to the patient at the end of each
segment play a major role in defining a patient's response. We hope that by using multi-
segment linear regression on patient data, we can define regions with stable hemodynamic
relations; each region has significant correlations on BP and HR, and on LAP and CO. We
will present the results in Section 3.2 on how well multi-segment linear regression defines
differences in a patient's response during his hospital stay.
We incorporated a variable, bval, in our multi-segment linear regression algorithm for
the purpose of controlling the relative number of segments that can be assigned to a hospital
stay. With a large bval, the algorithm might divide a hospital stay with 20 data points into
just one segment, while the same bval might assign 2 segments to a hospital stay with 50
data points. However, a smaller bval can give 3 data points to the same hospital with 20 data
points, and an exponentially increasing number of segments on 50 data points; the smaller
bval is, the larger the number of segments that are assigned. A larger number of segments
is also equivalent to smaller average time intervals per segment. The algorithm finds the
optimal division of a hospital stay into segments, which is dictated by bval, that minimizes
the variance for each fitted line. In other words, the connected segments are generated
using linear regression that breaks a segment when doing so decreases the variance by a
ratio set by bval. A larger bval requires a better improvement and therefore generates
smaller number of segments. We hypothesize that by decreasing bval low enough to capture
the state changes affecting hemodynamic relations, but at the same time, stay high enough
to justify each break, we can get better correlations on hemodynamic parameters in each
region. In the next chapter, we will look at whether or not the more segments assigned to
a hospital stay is equivalent to better correlations in each segment and the point at which
increasing the number of segments only decreases correlations.
2.4.2 Case Study
In Section 2.2.2, we made the hypothesis that the determining factor for a patient's BP-
HR relation over his hospital stay is whether or not he is taking drugs that disrupt the
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normal sympathetic stimulation, or the LAP-CO relation with Rank-Starling law. From
our hypothesis, patient 1469's hospital stay would be divided into 5 regions, as shown in
Figure 2-4 labeled with combinations of heparin and dopamine.
Using multi-segment linear regression, a patient's hospital stay would be divided into
various number of sections depending on the value of bval. With a bval of 10, the same
region in patient 1469 that had been sectioned off into 5 separate regions would instead
be divided into 6 regions. The six regions are shown in Figure 2-4 with the 6 connecting
dotted segments, along with the 5 regions determined using drug types. For our purposes,
we will not be looking at the slopes of the segments, but only at where each segment starts
and ends.
Notice how the region with dopamine alone has been divided into 2 regions with the 2
dotted segments. It might be the case that the disease state changed in the patient during
the dopamine region, or that he has been given another drug that has not been recorded.
With multi-segment linear regression, we are hoping that each time period found using the
segments have clearly defined hemodynamic relations. In other words, relationships on BP
and HR from 1.83217 until 1.83250, and from 1.83254 until 1.83265 might be different, but
both will be highly correlated. Here, we will be testing if multi-segment linear regression
provides an insight into things that define relations on BP and HR, or LAP and CO, other
than the factors we've considered in Sections 2.2 and 2.3.
2.5 Drug Effects Within Each Patient
Studies on potential drug effects are always performed before the drugs are introduced into
the public. Usually however, the studies are conducted with the drugs in isolation rather
than the combinations that commonly occur in the ICU. ICU patients have a myriad of
conditions that have the potential of changing the way drugs interact with their physiological
state. We believe that by doing an initial classification on the patients and their hospital
stay, as described in Sections 2.2.1 through 2.2.3, we can attribute certain types of drug
effects to each group of patients and time regions.
Instead of speculating on what might have brought about the differences in how patients
react to the same drugs, we will first look at how patients differ in their responses to the
addition and removal of specific drugs. Then we will examine the patients more closely for
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Figure 2-4: Comparison of state-based classification and multi-segment linear regression
with bval=5 on patient 1469's BP waveform.
similarities among patients and sections of hospital stays with the same kind of response.
For example, propranolol might decrease HR by 20 for patients in group A, but by 5 for
patients in group B, etc. The next two sections will present methods on quantifying and
classifying patient responses.
2.5.1 Consistent Hemodynamic Relations
To study the effects of particular drugs, we will be examining regions during which the drug
in interest has been removed or added, along with other sympathetic or non-sympathetic
drugs. Figure 2-4 illustrates a basic example of when dopamine has been added. Looking at
how patient 1469 reacts after he makes the transition from 'heparin' to 'heparin,dopamine'
would let us examine how the addition of dopamine effects his hemodynamic parameters.
In order to determine whether the addition of a drug increased or decreased the param-
eter, we compare the average of the measurements over the number of data points before
the drug has been added, and the average after the addition. And likewise for the removal
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of a drug. For taking the average before the drug application, we look at all data points
between the previous change in drug application and the one in question. As for the aver-
age after the drug application, all points after the application up until the next change are
considered.
However, drugs are not the only things that can have influences on when and how a
hemodynamic parameter changes; before the next change in drug application, the patient
might have stood up or incurred another condition that increases a parameter. Thus, we
limit the length of time span to only two hours. If the next change in drug application is
not until 3 hours later, we will only take the average of the measurements up to 2 hours
after the change that we are interested in. In other words, we take the shorter time span of
either 2 hours or time until next change. The same two hour limit applies to the average
before the change. By restricting the length of time we are examining, we hope to exclude
state changes that can only generate noise in our results if included.
2.5.2 Differences in Drug Dose
Many times we cannot see the effects of a drug until the drug dose is ramped up, either
because the effects are subtle or that the dose just isn't enough to bring out a reaction in
the patient. Furthermore, what if the dose has been reduced? How would we know that we
are actually looking at the effects of the drug and not something else?
heparin
'X
Dopamine = 7.5 mcgkgmin Dopamine = 10 mcgkgmin
0.5 11 11.5 12 12.5 13 13.5 hours
Region I Region 2 Region 3
Figure 2-5: Sectioning of a hospital stay based on drug type.
Let's say we are interested in how giving a patient dopamine changes his hemodynamic
parameters. Figure 2-5 gives an illustration of the things that we take into account when
examining the effects. The time span from hour 0.5 to hour 3.5 is divided into three regions
based on the drugs the patient is taking. Region 1 covers the time when only heparin is
given to the patient, whereas region 3 is for when only dopamine is given.
In region 2, the patient starts receiving dopamine at 7.5 mcgkgmin in addition to heparin.
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This region takes into consideration of when the drug dose has been ramped up. As long
as the time of the increase in dose (7.5 to 10 mcgkgmin) is within 2 hours of the previous
change in drug application (heparin-+heparin + dopamine 7.5 mcgkgmin), the region with
10 mcgkgmin of dopamine is taken into account, until the next change in state (the patient
stops receiving heparin). After the patient stops receiving heparin, we can no longer factor in
the effects caused by the 10 mcgkgmin of dopamine from hour=2.5 to hour=3.5; removing
heparin might have caused changes in parameters that we can mistaken for effects from
dopamine. Thus, when we take the averages of measurements before and after hour=1, we
look at points between hour 0.5 and 1 (region 1), and between hour 1 and 2.5 (region 2),
respectively.
As long as the patient is receiving the same types of drugs, or stays within the 2 hour
limit, the measurements are factored in even when the dose has been ramped up. The same
principle applies to when the drug has been removed or when the dose has been reduced.
When a patient starts to receive a smaller dose of the same drug, we might not be able to
see the usual increase or decrease in a parameter when the drug was given in a higher dose,
but the drug effects are still sustained in the patient.
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Chapter 3
Results
Sections 3.1 and 3.2 will focus mainly on presenting the correlations between (A)BP and
(A)HR, and LAP and CO using state-based classification (described in Sections 2.2 and
2.3) and multi-segment linear regression (discussed in Section 2.4), respectively. The last
section will present the observed drug effects from dobutamine, dopamine, nitroglycerin,
nitroprusside, levophed, and neosynephrine.
The first two sections will look at how one parameter A changes in response to a change
in another parameter B - does A change in the same direction as B? Or in a different
direction? How is the change in A related to the change in B? In the terms of correlation
coefficients, the closer a coefficient is to 1, the more positively correlated two parameters
are; if parameter A increases, then parameter B also increases proportionally. On the other
hand, the closer a correlation coefficient is to -1, the more negatively correlated the two
parameters are; if parameter A increases, then parameter B decreases proportionally. If the
coefficient is closer to zero than 1 or -1, then the more randomly one parameter changes in
response to a change in the other parameter.
All coefficients (before normalizations) are calculated using Equation 3.1, where cov is
the covariance function, and both paramA and param-B are one-column matrices with
the observations.
cv(param-A, param-B)
correlation-coef icient = ( a paramA parammB) (3.1)
y/cov (param-A, param-A) * cov (param-B, param-B)
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3.1 Correlations Using Case Breakdown Analysis on Patient
State
Each correlation coefficient is obtained by first using Equation 3.1 on all data points from
each patient that satisfy all the constraints in each table - number of sympathetic drugs
(SS), patient disease state (arrhythmia and cardiomyopathy, and pulmonary hypertension),
region's heart rhythm (arrhythmic or non-arrhythmic), range of ABP and LAP. Then the
average is taken over the sample space of patients with valid data points to obtain the PN
and P correlations.
For the rest of this section, we will use the term 'PN correlations' to refer to unaltered
average correlation coefficients that can be either positive or negative (the average of a
positive correlation and a negative correlation can turn out to be zero). The term 'P
correlations' will be used to refer to the results obtained by normalizing the absolute values
of correlation coefficients, rather than taking signs into consideration.
P correlations give us an insight into how closely correlated two parameters are in each
patient's set of valid data points; both negative and positive coefficients are significant as
long as their absolute values are close to 1, even if the two parameters are correlated in
different ways in different regions.
However, a comparison between a P correlation and its PN counterpart lets us examine
how closely related each patient is to each other in terms of the similarities between hemo-
dynamic relations among different patients; the larger IP - PNI is, the more negatively
correlated the two parameters are in the group of patients examined. If the absolute value
of the difference is close to zero, given significant PN correlations, then we know that a ma-
jority of relations are positively correlated. However, the combination of a small IP - PN
and insignificant PN correlations would mean that the two parameters are not correlated
at all.
3.1.1 ABlood Pressure -+ AHeart Rate
Sympathetic Stimulation
Both PN and P correlations on ABP and AHR with classification on disease state (ar-
rhythmic or non-arrhythmic in Section 2.2.1) and the number of SS drugs (dobutamine,
dopamine, or epinephrine in Section 2.2.2) are shown in Tables 3.1 and 3.2.
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For arrhythmic patients, all correlations shown in Table 3.1 are in the low positive range,
with little difference between a PN correlation and its P counterpart (small |P - PN|). In
another words, BP and HR, in a vast majority of patients, change in the same direction
more often than they do in the opposite direction. However, all the P correlations are under
0.5. This indicates that in each set of data defined for each arrhythmic patient, there is a
lack of regularity in the direction of change, and inconsistent proportion of change in HR
in response to change in BP. We can see, however, that BP and HR are better correlated
in non-arrhythmic than arrhythmic regions when SS=0 or SS=1 (higher P correlations).
In arrhythmic regions, BP and HR begin to change more and more in the opposite
direction when the value of SS increases. But we do not see the same consistency in non-
arrhythmic regions; the percentage of changes in negative directions decreased when we
increased SS from 0 to 1, but increased when we increased SS from 1 to 2.
As is the case for arrhythmic patients, BP and HR in non-arrhythmic patients (Table
3.2) also changes irregularly in respect to each other, and changes in the same direction
dominate for a majority of the patients under all values of SS. In both arrhythmic and non-
arrhythmic region in non-arrhythmic patients, the frequency at which BP and HR change
in the opposite direction increases steadily when the value of SS increase from 0 to 2.
For each group of patients with the same SS value for both patient sets, we can say
that the patients are similar in that BP and HR change in the same direction at a higher
frequency than they do in the opposite direction. Under the same SS constraints, regions
in non-arrhythmic patients (arrhythmic or non-arrhythmic) have higher correlations (Table
3.2) than regions in arrhythmic patients, except when SS=1. This indicates that BP and HR
are better correlated in non-arrhythmic patients compared to arrhythmic patients, within
the regions defined using drug type classification.
Non-arrhythmic regions in non-arrhythmic patients show a steady decrease in how well
BP and HR are correlated when we increased SS, while there are inconsistencies in how
BP and HR are correlated in other combinations of regions and patients in different dis-
ease states (arrhythmic and non-arrhythmic). P correlations in arrhythmic regions in non-
arrhythmic patients and non-arrhythmic regions in arrhythmic patients show the same kind
of trend where BP and HR become less correlated when SS increases from 0 to 1, but more
correlated when SS increases from 1 to 2, while P correlations in arrhythmic regions in
arrhythmic patients change in the completely opposite direction.
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SS arrhythmic regions non-arrhythmic regions
value PN correlations P correlations PN correlations P correlations
SS=0 0.2683(1001) 0.3115(1001) 0.2548(666) 0.3223(666)
SS=1 0.1777(1311) 0.2743(1311) 0.3007(55) 0.3361(55)
SS=2 0.1588(485) 0.2757(485) 0.0284(7) 0.2112(7)
SS=1,2 1 0.1804(1469) 0.2703(1469) 0.1967(9) 0.1967(9)
Table 3.1: Average PN and P correlation coefficients on ABP and AHR, for arrhythmic
patients over both arrhythmic and non-arrhythmic regions with specified number of sympa-
thetic drugs. Each number in parenthesis represents the number of patients used. N=number
of drugs patient is taking, SS=number of sympathetic drugs
SS arrhythmic regions non-arrhythmic regions
value PN correlations P correlations PN correlations P correlations
SS=0 0.2742(1940) 0.3473(1940) 0.2760(1259) 0.3348(1259)
SS=1 0.1630(1999) 0.2992(1999) 0.1932(57) 0.2845(57)
SS=2 0.1658(473) 0.3121(473) 0.0599(6) 0.2727(6)
SS=1,2 0.1613(2176) 0.2902(2176) 0.2014(13) 0.2498(13)
Table 3.2: Average PN and P correlation coefficients on ABP and AHR, for non-arrhythmic
patients over arrhythmic and non-arrhythmic regions with specified number of sympathetic
drugs.
Correlations in Different Ranges of ABP
A complete set of correlations on ABP and AHR are shown in Tables 3.3 through 3.6.
The four tables are divided into two for arrhythmic and two for non-arrhythmic patients.
One table from each group presents both PN and P correlations over arrhythmic regions
while the other table in each group is for non-arrhythmic regions. All correlations are
calculated after performing classification on data points using disease state in both regions
and patients, number of SS drugs, and range of ABP.
Constraint on the range of ABP corresponds to the classification method described in
Section 2.2.3. Each of the PN/P correlations shown in the four tables includes only data
from either arrhythmic or non-arrhythmic patients and regions that satisfies both the value
of SS and the specified ABP range. For example, for an arrhythmic patient, if at some
point during their hospital stay they are taking no sympathetic drugs (SS=0), if there
are times when BP decreased in this non-sympathetic region, and if this region is non-
arrhythmic (Table 3.4), then he would have been one of the 336 patients with an average
PN correlation of 0.1632.
It is very likely that in this group of 336 patients, there are some whose HR changes
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in response to BP with regularity and in fairly consistent proportions, and some with
irregularity. However, we are not interested in groups of patients with differing responses
from HR. We are only interested in high average PN correlations (whether close to -1 or
1). A high correlation shows that the patients in the group have both of the two properties
we look for - similarity in the relationships between BP and HR among the patients, and
highly correlated BP and HR in a majority of the patients.
All of the PN and P correlations for arrhythmic patients are under 0.3 for arrhythmic
and non-arrhythmic regions alike, shown in Tables 3.3 and 3.4. With small differences
between each pair of PN and P correlations, the direction of change for HR in respect to
BP in each patient is predominantly in the same direction for all ranges of ABP under all
sets of constraints, with one exception when SS=2 and 15<ABP<30.
There are no observable differences between the lower three ranges of ABP in both tables
for arrhythmic patients in terms of how often BP and HR changes in the same direction.
We can see higher percentages of negative correlations in 15<ABP<30 in its 4 patient
groups (for both arrhythmic and non-arrhythmic regions) than in the other patient groups
under the first three ranges. In another words, BP and HR are becoming more negatively
correlated as the change in BP gets larger. In all ranges of ABP in arrhythmic regions, the
percentage of negative correlations increases as we increase the value of SS. In contrast, the
trend in how BP and HR changes varies for non-arrhythmic regions in arrhythmic patients;
percentage of changes in the opposite direction as we increase SS decreases under ABP<0,
decrease then increase under -10< ABP<10, increases under 0<ABP<20 and 15<ABP<30.
Comparisons between Tables 3.3 and 3.4 also show that 70% of the time, we can see
slightly better correlations in non-arrhythmic regions than in arrhythmic regions under the
same ABP range and SS constraints. Furthermore, classifying using both SS and ABP
range gives higher P correlations than classifying with ABP range alone (all) under all
ranges of ABP, except when SS=2 or 15<ABP<30.
Similar to arrhythmic patients, a comparison between the PN and P correlations for
non-arrhythmic patients in both arrhythmic and non-arrhythmic regions (Tables 3.5 and
3.6) also shows that BP and HR change in the same direction more often than they do in
the opposite direction in all but one of the patient groups. With both PN and P correlations
in the low range under 0.3, there is no evidence of consistent and significant relationship
between the two parameters among the regions defined using ABP range and SS.
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SS PN/N correlations for arrhythmic patients over arrhythmic regions
value ABP<0 -1O<ABP<10 0<ABP<20 15<ABP<30
All 0.1403:0.2200:1728 0.1411:0.1932:1788 0.1312:0.1981:1706 0.0970:0.2174:559
SS=O 0.1769:0.2494:864 0.1621:0.2153:934 0.1558:0.2155:845 0.1071:0.2381:281
SS=1 0.1202:0.2415:1090 0.1165:0.2044:1196 0.1130:0.2199:1055 0.0761:0.2474:165
SS=2 0.0955:0.2468:394 0.1162:0.2194:443 0.0944:0.2316:368 0.0735:0.2085:38
Table 3.3: Average PN and P correlation coefficients on ABP and AHR, for arrhythmic
patients over arrhythmic regions with the specified number of SS drugs and ranges of ABP.
Each PN correlation is colon-separated with its P correlation, then by a colon-separated
number of patients used for obtaining each pair of PN and P correlations. N=number of drugs
patient is taking, SS=number of sympathetic drugs
SS PN/N correlations for arrhythmic patients over non-arrhythmic regions
value ABP<O -10<ABP<10 0<ABP<20 15<ABP<30
All 0.1632:0.2471:336 0.1445:0.2052:354 0.1782:0.2345:326 0.1212:0.2560:108
SS=0 0.1653:0.2659:558 0.1680:0.2296:616 0.1856:0.2372:536 0.1048:0.2356:162
SS=1 0.1985:0.2611:47 0.1787:0.2333:53 0.1257:0.1959:45 0.0951:0.2362:19
SS=2 0.1720:0.2149:6 0.1069:0.2662:7 0.0170:0.2911:5 -0.1841:0.1841:1
Table 3.4: Average PN and P correlation coefficients on ABP and AHR, for arrhythmic
patients over non-arrhythmic regions.
The two tables for non-arrhythmic patients over arrhythmic (Table 3.5) and non-arrhythmic
regions (Table 3.6) show that 81% of the time P correlations over non-sympathetic regions
are higher than that over sympathetic regions (SS=1, SS=2). As is the case with arrhyth-
mic patients, the percentage of negative correlations under 15<ABP<30 in both types of
regions are higher than that under the other 3 ranges of ABP. The percentage of BP and
HR changing in the opposite direction increases as we increase the value of SS, for both
arrhythmic and non-arrhythmic regions in non-arrhythmic patients. Two exceptions are
under -10<ABP<10 over non-arrhythmic regions where the percentage decreased when SS
increased, and under 15<ABP<30 over non-arrhythmic regions where we see a decrease
then an increase when SS increase from 0 to 2.
In summary, HR changes irregularly in response to changes in BP for non-arrhythmic
patients, and there are no observable similarities between patients in each group due to
low P correlations. We can still see slightly better correlations in classified regions than
non-classified regions using SS (as is the case for arrhythmic patients).
Non-arrhythmic patients have slightly better correlations than arrhythmic patients 81%
of the time under the same SS, ABP range, and region state (arrhythmic or non-arrhythmic),
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SS PN/P correlations for non-arrhythmic patients over arrhythmic regions
value ABP<0 -10<ABP<10 0<ABP<20 15<ABP<30
All 0.1564:0.2514:2881 0.1312:0.2090:3065 0.1322:0.2275:2807 0.0844:0.2203:763
SS=0 0.1974:0.2751:1603 0.1615:0.2283:1777 0.1676:0.2513:1542 0.1201:0.2317:461
SS=1 0.1030:0.2588:1610 0.1009:0.2205:1807 0.0980:0.2327:1531 0.0158:0.2263:229
SS=2 0.1103:0.2724:352 0.1119:0.2265:416 0.0726:0.2354:321 0.0420:0.2110:26
Table 3.5: Average PN and P correlation coefficients on ABP and AHR, for non-arrhythmic
patients over arrhythmic regions.
SS PN/P correlations for non-arrhythmic patients over non-arrhythmic regions
value ABP<0 -10<ABP<10 0<ABP<20 15<ABP<30
All 0.1742:0.2586:861 0.1522:0.2194:901 0.1675:0.2442:813 0.1415:0.2612:238
SS=0 0.1861:0.2720:1066 0.1604:0.2309:1172 0.1782:0.2525:1009 0.1358:0.2591:268
SS=1 0.1044:0.2274:47 0.1920:0.2432:52 0.1287:0.2299:39 0.2961:0.3056:6
SS=2 -0.0478:0.2635:6 0.2472:0.2472:8 0.0772:0.1250:6 -0.0895:0.0895:1
Table 3.6: Average PN and P correlation coefficients on ABP and AHR, for non-arrhythmic
patients over non-arrhythmic regions.
indicating that our hypothesis that better correlations on BP and HR can be observed in
non-arrhythmic patients. However, P and PN correlations for both patient sets stay mostly
under 0.3, and the majority on higher correlations in non-sympathetic than in sympathetic
regions for non-arrhythmic patients (81%) does not hold for arrhythmic patients where it
is a 50-50 split.
3.1.2 Left Atrial Pressure -> Cardiac Output
Correlations in Different Ranges of LAP
Table 3.7 provides a summary of the PN and P correlations on LAP and CO under different
ranges of LAP for non-hypertensive patients. Due to difficulties in taking CO measurements
non-invasively, the number of patients in the sample space significantly decreased from what
was available for BP and HR.
Looking at Table 3.7, there is a gradual decrease, then increase in P correlations on
LAP and CO as the range of LAP moves away from the upward slope towards the plateau
in the Frank-Starling curve (Figure 2-3). The gradual decrease agrees with our hypothesis
that as LAP increases, CO becomes less and less affected by changes in LAP.
Comparisons between each pair of P and PN across the whole range of LAP further show
that the relation between LAP and CO is becoming more positive as LAP moves along the
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Frank-Starling curve towards 25, but at the same time, also becoming less correlated. Once
LAP goes over 25, CO responds to changes in LAP with increasing regularity again, albeit
low correlations.
correlation type 0<LAP<10 I 10<LAP<20 [20<LAP<25 I 25<LAP<30 30<LAP
PN -0.1265 -0.0205 -0.0247 0.0383 0.0074
P 0.2870 0.2525 0.2023 0.2184 0.2654
# of data points 209 5870 3747 2036 1461
# of patients 12 164 100 59 33
Table 3.7: Average PN and P correlation coefficients on LAP and CO for non-hypertensive
patients with classification on range of LAP, and the number of data points and patients
used for obtaining each coefficient.
3.2 Correlations Using Multi-Segment Linear Regression
The next two sections present the results obtained using multi-segment linear regression,
which generates a set of connected segments on BP and LAP values for each patient,
independently. Hemodynamic relations between BP and HR, and LAP and CO are then
examined in each of the regions defined by the connected segments. This section also uses
PN and P correlations. Here, however, coefficients are averaged over all the segments defined
for a hospital stay, rather than over all patients as described in Section 3.1.
Tables 3.8 and 3.9 each contains the parameter bval, previously described in Section
2.4.1, that dictates the relative number of connected segments assigned to each patient's
hospital stay. The smaller bval is, the smaller the average time interval per segment due to
the increased number of segments over a hospital stay.
3.2.1 Blood Pressure -+ Heart Rate
Average Correlations on BP and HR
Table 3.8 shows a breakdown of patients based on their PN and P correlations on BP
and HR across 3 different values of bval. Correlations are obtained using multi-segment
linear regression to divide each BP waveform into contiguous segments, then calculating the
correlation between BP and HR for each segment, and finally averaging over all segments
in a hospital stay. Discrepancies in the total number of patients under each of the bvals
in Table 3.8 is due to the fact that a segment is considered only when it contains at least
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10 entries of BP and HR. Patients are excluded if they do not have any regions with 10 or
more entries. Decreasing bval reduces the average time interval at the same time it reduces
the probability of containing 10 or more entries within shorter time intervals. Figure 3-1
shows the same distribution of patients, in percentages, in different ranges of PN and P
correlations.
PN correlations for most of the patients, regardless of bval, are concentrated around the
low positive range between 0 and 0.2 (Table 3.8). Looking at the plot for PN correlations
in Figure 3-1, the shapes of the bval curves stay identical across bval-50, bval-25, and
bval=10. However, notice the relative positions of the bell curves. As the average time
interval per segment decreases, the center of each curve gradually shifts to the right with
higher percentages of patients, indicating a positive increase in PN correlations as the
number of segments increased, albeit low correlations.
Low PN correlations can be the result of different hemodynamic relations among the
defined regions in a patient, if some are negatively correlated and some positively correlated.
However, with a large number of patients also concentrated around the low positive range
for P correlations shown in the P correlation plot in Figure 3-1, and a decreasing number
as correlations move towards one, the relation between BP and HR is obviously not clearly
defined in any of the regions. If a low PN correlation is accompanied by a high P correlation,
then we know there are significant negative correlations, which is not the case here. From
this, we can see that HR increases/decreases irregularly in response to changes in BP for
the numbers of segments we tried.
Increasing the number of segments assigned to each patient's hospital stay improves the
relation between BP and HR in each patient; HR is starting to change in the same direction
as BP changes more often than it does in the opposite direction. Furthermore, the graph
on P correlations in Figure 3-1 shows that, even with the curves centered around the same
range, relations between BP and HR in the regions of each hospital stay are becoming more
defined as the number of segments increases; the percentage of patients in the higher P
correlation ranges increases as bval decreases, while there are fewer and fewer patients in
the lower ranges.
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range of # of patients in PN range # of patients in P range
PN/P correlations bval=50 bval=25 J bval=10 bval=50 bval=25 [bval=10
-1.0 -- 0.8 1 1 1 - -
-0.8 -- 0.6 11 7 6 - -
-0.6 -- 0.4 37 35 25 - -
-0.4 -- 0.2 102 93 70 - - -
-0.2 --+0 202 197 152 - - -
0 -* 0.2 330 310 324 471 358 199
0.2 -+ 0.4 317 347 366 468 517 522
0.4 -- 0.6 186 183 197 235 286 400
0.6 -0.8 47 54 62 58 65 81
0.8 -1.0 9 9 10 10 10 11
total # of patients 1242 1236 1 1213 1242 1236 1213
Table 3.8: Distribution of patients on ranges of PN/P correlations on BP and HR, using
multi-segment linear regression. The number of segments defined for each patient increases
as bval decreases.
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Changes in Correlations with Increasing Number of Segments
Figure 3-2 presents a summary of how hemodynamic relations change in each patient as
bval decreases to increase number of segments increase. Each x-value is a pair of decreasing
bval's and indexes the percentages of patients with increased PN correlation, increased P
correlation, or with no change in correlations as the average time interval shortens with the
change in bval. A patient is under 'no change' if the average correlation between BP and
HR per segment did not change even when the number of segments increased. The category
'increased P correlations' refers to patients whose P correlations on BP and HR increased.
On the other hand, when a patient whose correlation on BP and HR in each of the regions
moves closer to 1 or -1, then he is put under 'increased PN correlations'.
Above each x-value is a pair of colon-separated values that represent the total number of
patients in each group and on average, how much the coefficients increased per patient. For
example, when the average time interval per segment decreased with the change of bval from
25 to 10 (Figure 3-2), 49% of the patients did not have changes in their correlations on BP
and HR, while 14% increased their P correlations. The rest 37% increased PN correlations.
This particular group of patients (total of 1213) increased an average of 0.1159 on their BP
and HR correlations.
The x-values in each of the two plots in Figure 3-2 are all placed in an order of increasing
number of segments between the change in bval(s). With the number of segments increasing
exponentially as bval decreases, the change in the number of segments in a patient when bval
decreases from 50 to 10 is greater than the change between a bval of 25 and 10, and likewise
for the increase from 50-*25 to 25-+10. In another words, in the right plot of Figure 3-2,
a patient's hospital stay might have been assigned with 1 segment when bval=50, 2 when
bval=25, 5 when bval-10, and 10 when bval=5. This gives an increase of 5 segments for
10--5, 8 for 25-+5, and 9 for 50->5.
Percentage of patients who increased either their P or PN correlations increased as
we increase the number of segments assigned to each patient as shown in Figure 3-2 with
50-+25, 25-+10, 50-40, and with 10-+5, 25-+5, and 50-+5. With the largest number of
segments assigned to a patient when bval is 10 (left plot), and the smallest number when
bval is 50, we can see that the third x-value (50-+10) has the highest percentage and amount
of increase among the three x-values in Figure 3-2. The same thing can be argued for the
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Figure 3-2: Breakdown on how patients' correlations on BP and HR change when bval is
changed to 25 or 10 (left plot), or to 5 (right plot) - no change, increased P correlations,
and increased PN correlations (either towards 1 or -1). The pairs of numbers separated by
colons represent the total number of patients and average increase on correlations for each
patient group. The x-values in each plot are placed in the order of increasing changes in
the number of segments between the bvals in each x-value.
three bval pairs in plot to the right in the same figure. From the pair of colon-separated
numbers in both plots, we can see that the average correlation per patient increases when
the average time interval decreases. Furthermore, patients also increase their likelihood of
upping PN/P correlations as we reduce the average time interval.
3.2.2 Left Atrial Pressure -- Cardiac Output
Average Correlations on LAP and CO
Table 3.9 presents a breakdown of the number of patients for each range of correlations on
LAP and CO, organized in the same way as Table 3.8 for BP and HR. The distribution
of PN correlations on LAP and CO resembles a bell curve centered around zero, showing
either minimal similarity or irregularity in LAP's response among regions defined using
multi-segment linear regression on LAP waveforms. Having regions with differing relations
between CO and LAP in the same hospital stay is intuitive if we think about state changes
that alter the hemodynamic relations.
However, the same table also shows that P correlations for a majority of patients stay
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range of # of patients in PN range # of patients in P range
PN/P correlations bval=50 bval=25 bval=10 bval=50 bval=25 bval=10
-1.0 -+ -0.8 0 4 1 - - -
-0.8 -+ -0.6 2 16 5 - - -
-0.6 -+--0.4 7 32 17 - - -
-0.4 -- 0.2 14 72 29 - - -
-0.2 --+0 23 94 48 - - -
0 -* 0.2 15 72 62 31 122 59
0.2--+0.4 4 47 33 22 158 106
0.4-40.6 4 15 13 14 52 37
0.6-+40.8 0 12 4 2 28 9
0.8 -+ 1.0 1 1 2 1 5 3
total # of patients 70 365 214 70 365 214
Table 3.9: Distribution of patients on ranges of PN/P correlations on CO and LAP, using
multi-segment linear regression on LAP.
in the 0 to 0.2 range. With the largest concentration of patients in the low positive range
for both P and PN correlations, we can see that most of the patients do not have significant
correlations on CO and LAP in the regions assigned to their hospital stays, as is the case
for the distribution of correlations for BP and HR in Table 3.8. So at the same time that
CO reacts differently to changes in LAP at different regions in the same patient, it is also
true that the relation between CO and LAP is not clearly defined in the regions.
Percentages of patients in each PN and P correlation range are plotted in Figure 3-3.
Compared to the distribution plots for BP and HR (Figure 3-1), these plots show more
irregularity in how the number of segments affects the relationship between CO and LAP.
The plot on P correlations shows extremely varied results. Shortening the average time
interval per segment does not necessarily make correlations between CO and LAP more
significant, as shown in the plot on the right in Figure 3-3 with intersecting bval curves.
In the plot on PN correlations in the same figure, there is a greater increase in percent-
ages in the upper ranges when bval is changed from 50 to 10. When bval is 25, however, the
percentage of patients with higher correlations does not always increase, compared to when
bval=50, which is in agreement with the plot on P correlations. Furthermore, the relative
positions of the three bval curves for PN correlations show that increasing the number of
segments inconsistently increases the probability of having regions with LAP that changes
in the same direction as CO.
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Table 3.9.
PN correlation on CO and LAP from
Changes in Correlations with Increasing Number of Segments
Figure 3-4 shows a distribution of how patients' correlations on LAP and CO change as bval
changes. The x-values in both plots are placed in the same order as the ones in Figure 3-2
for BP and HR. Contrary to the breakdown for BP and HR shown in Figure 3-2, a majority
of patients here did not change in terms of how CO increases/decreases in response to LAP
as the number of segments increased; the percentage of patients with increases in PN or P
correlations is much lower than the percentage with no change.
Shown in the two plots in Figure 3-4, the average correlation increases steadily while
shortening the time interval per segment. However, if we were to compare the average
correlations between the two plots, we can see that while there is a greater increase in
the number of segments for 50->5 than for 50-*10, 50-5 has a slightly lower increase in
average correlation (0.1307 vs. 0.1315). This leads us to think that shortening the average
time interval can increase correlations only up to a certain point (bval=10 in this case),
after which shorter time intervals can only generate more noise. The same can be argued
for the drop in the number of patients increasing their correlations and a lower increase in
correlation when comparing x = 25 -> 5 with x = 50 -> 10.
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3.3 Observed Drug Effects
This section will provide a summary of the ways in which dobutamine/dopamine, nitroglyc-
erin/nitroprusside, and neosynephrine affect BP, CO, HR, and LAP. Although the therapy
prediction model also incorporated digitalis and hydralazine as the model drugs for inotropic
agents and vasodilators, there was not enough data in MIMIC II to make any observations,
and thus, neither of these two drugs will be studied in this thesis.
3.3.1 Overview
Tables 3.11 through 3.16 show the observed drug effects when either dobutamine, dopamine,
nitroglycerin, nitroprusside, or neosynephrine is added or removed in addition to other non-
sympathetic drugs. Each set of added drug types represents transition from a region without
the drugs in interest (dobutamine, dopamine, nitroglycerin, nitroprusside, neosynephrine,
non-sympathetic drugs), to a region with the drugs of interest. And vice versa for the sets
of removed drugs.
Each table reports the total number of regions during which the specified drug types
were either added to or removed from the previous region, the number of additions/removals
that caused an increase in each of the hemodynamic parameters (T), and the number that
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ICD9 codes Idiseases
393-398 chronic rheumatic heart disease
401-405 hypertensive disease
410-414 ischemic heart disease
415-417 diseases of pulmonary circulation
420-429 other forms of heart disease
Table 3.10: ICD9 code with corresponding diseases.
caused a decrease (1). Numbers in parenthesis represent the number of regions, out of
the ones under T and I that have abnormal heart rhythms (Section 2.2.1). Whether the
added/removed drug types caused the parameter to increase or decrease is determined by
the method previously described in Section 2.5.1. We will be referring to these regions that
satisfy the constraint of either having the specified drug types removed or added as 'valid'.
The second half of the table reports the total number of patients examined (total),
and out of which, how many had more valid regions during which the parameter increased
than decreased (avg=T), and how many had more regions that decreased than increased
(avg=1). In addition, 'E =T' gives the number of patients who had an overall increase over
the valid regions in their hospital stay, while 'E =' gives the number of patients with an
overall decrease. Let's say a patient has three valid regions during which dobutamine has
been added. If BP increased 5 mmHg in one region, increased 3 in the other region, and
decreased 4 in the last region, then he would have increased an overall of 4 mmHg over all
valid regions in his hospital stay. Thus, he would be one of the 19 patients under E =T
who had an overall increase in BP when dobutamine has been added (Table 3.11).
3.3.2 Changes in Blood Pressure, Cardiac Output, Heart Rate, and Left
Atrial Pressure
Beta Blockers: Dobutamine and Dopamine
To study the effects of dobutamine, a sympathetic drug, we looked at how the addi-
tion/removal of dobutamine along with other non-sympathetic drugs changes the hemody-
namic parameters, BP, CO, HR, and LAP. Looking at Table 3.11, giving only dobutamine
brought an overall decrease in BP in 129 out of 233 patients, increase in CO in 93 out of
113 patients, increase in HR in 204 out of 283 patients, and decrease in LAP in 115 out of
205 patients.
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However, the breakdown on the types of diseases attributed to patients with an increase
and decrease in each of the parameters (left two plots in Figure 3-5) does not show a
significant difference between the two groups of patients; a majority of patients in both
groups have some form of heart disease assigned ICD9 code from 420 to 429, with a difference
of only a few patients with ICD9=393 through ICD9=398 between the group with increase
and group with decrease in any of the four parameters. Table 3.10 shows a grouping of the
ICD9 codes and their corresponding diseases, used in Figures 3-5 through 3-10. A patient
can belong to more than one ICD9 category if he has multiple diseases spanning different
disease categories.
When dobutamine has been removed (Table 3.11), the effects on CO and HR reversed.
In another words, whereas the addition of dobutamine caused an increase in both CO and
HR, the removal caused a decrease in both CO and HR in a majority of patients. A majority
also had a decrease in LAP when dobutamine is added, albeit the small difference between
the number of patients with increases and with decreases.
Whether dobutamine has been added or removed, the change increases and decreases
BP in almost an equal number of patients in both cases, with no difference between the
4 patient groups (BP increased when dobutamine is added or removed and BP decreased
when dobutamine is added or removed).
Adding or removing dopamine (Table 3.12), a sympathetic drug, shows that it has the
same effects as dobutamine - increased CO and HR when added and decreased CO and HR
when removed. It is ambiguous in how dopamine affects BP and LAP since the disease
distribution for both parameters do not seem to differ by more than 5% in each disease
category.
Furthermore, neither drug seems to cause any significant change in LAP, which almost
has a 50-50 split in the number of patients with increase and with decrease during both
addition and removal of the two drugs. However, dopamine seems to have effects on BP on a
larger percentage of patients than dobutamine does; BP increased in a majority of patients
when dopamine has been added whereas the removal caused only half of the patients to
have an increase in BP.
There is no significant difference in the number of patients in each category of ICD9
code both between groups with increase and decrease when dopamine is being given or
taken out (Figure 3-6).
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drug # of regions # of patients
type(s) Param I [ tot avg=I avg=j E =1 E =1 I tot
+dob BP 155(58) 170(55) 328 90 117 102 129 233
CO 110(37) 21(6) 136 90 15 93 16 113
HR 279(88) 90(33) 390 198 55 204 66 283
LAP 118(45) 145(44) 270 81 108 88 115 205
+dob & BP 7(1) 13(3) 21 7 13 7 13 21
+1 nSS CO 8(0) 3(0) 11 8 3 8 3 11
HR 11(1) 13(4) 24 11 13 11 13 24
LAP 8(3) 9(1) 19 8 9 8 9 19
-dob BP 198(63) 208(73) 408 144 133 160 148 309
CO 36(13) 116(39) 157 29 101 30 104 137
HR 146(45) 312(100) 476 91 225 102 242 358
LAP 181(54) 155(51) 349 139 112 150 122 281
-dob& BP 5(1) 7(2) 12 5 7 5 7 12
-1 nSS HR 4(1) 11(1) 17 4 11 4 11 17
LAP 8(1) 5(2) 13 8 5 8 5 13
Table 3.11: Observed drug effects when dobutamine (dob) and other specified drugs were
added (+) or removed (-) at the same time.
parameter stayed the same, while patients are
Regions unaccounted for means that the
unaccounted for when either they have an
even number of regions with increase and decrease, or when the parameter did not change
overall. drug type=types of drugs added, dob=dobutamine, nSS=non-sympathetic drugs, 'avg=l'=there
are more regions with an increase in the parameter than with a decrease in patient, 'avg=l'=more regions
with decrease
overall
than with increase, 'E =T'=increased overall over all examined regions, 'E =1'=decreased
drug # of regions # of patients
type(s) Param T I tot avg=T [avg=jI E =TE =I tot
+dop BP 557(165) 326(76) 888 324 180 352 198 552
CO 78(21) 27(10) 113 69 22 71 22 99
HR 779(207) 396(91) 1218 474 199 508 221 743
LAP 194(61) 146(37) 358 130 104 133 118 259
+dop & BP 19(4) 23(7) 42 19 22 19 22 41
+1 nSS CO 5(0) 2(1) 7 5 2 5 2 7
HR 36(12) 21(5) 61 34 20 35 20 59
LAP 8(0) 13(5) 21 8 13 8 13 21
-dop BP 517(133) 610(161) 1137 317 349 342 396 744
CO 44(7) 66(18) 118 37 59 40 61 108
HR 460(96) 941(263) 1467 271 604 299 635 961
LAP 215(58) 238(68) 473 154 164 164 183 362
-dop & BP 26(4) 20(6) 47 24 18 25 19 45
-1 nSS HR 24(5) 30(7) 56 23 28 24 28 54
LAP 9(3) 11(0) 21 9 11 9 11 21
Table 3.12: Observed drug effects when dopamine (dop) and other specified drug types were
added (+) or removed (-). Number in parenthesis is the number of regions under either I
or I that have abnormal heart rhythms.
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Figure 3-5: Distribution of diseases (ICD9 codes from 393 to 398, 401 to 405, 410 to 414,
415 to 417, and 420 to 429 in Table 3.10) on patients with an increase or decrease in each of
the parameters, BP, CO, HR, and LAP, when dobutamine has been added (+) and removed
(-). 'Increase' corresponds to the patient groups under Z =T, and 'Decrease' to the patients
groups under E =J, in Table 3.11.
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Figure 3-6: Distribution of diseases on patients with an increase or decrease in each of
parameters, BP, CO, HR, and LAP, when dopamine has been added (+) and removed
'Increase' from E =T and 'Decrease' from E =1 in Table 3.12.
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drug # of regions # of patients
type(s) Param T I tot avg=T avg=1J E=T [E=1 tot
+nitro BP 918(204) 1379(315) 2312 358 719 414 816 1234
CO 340(122) 217(71) 570 221 141 245 156 405
HR 1429(243) 1025(211) 2605 696 489 799 559 1407
LAP 520(156) 804(234) 1373 246 444 302 497 822
+nitro & BP 56(13) 55(11) 113 54 53 55 54 111
+1 nSS CO 19(8) 10(1) 31 19 10 19 10 31
HR 62(8) 54(9) 127 61 54 61 54 125
LAP 32(7) 35(9) 73 32 35 32 35 73
-nitro BP 1016(220) 1290(269) 2324 475 686 561 777 1341
CO 271(78) 281(80) 566 197 193 209 208 428
HR 1000(205) 1589(236) 2756 501 852 561 971 1606
LAP 727(200) 604(161) 1379 432 333 496 377 890
-nitro & BP 53(8) 56(16) 112 49 50 51 52 106
-1 nSS CO 15(3) 8(6) 27 15 8 15 8 27
HR 48(9) 80(13) 135 46 74 47 75 129
LAP 48(13) 23(5) 74 47 21 48 21 71
Table 3.13: Observed drug effects when nitroglycerin (nitro) and other specified drug types
were added (+) or removed (-). Number in parenthesis is the number of regions under either
T or I that have abnormal heart rhythms. nitro=nitroglycerin
Vasodilators: Nitroglycerin and Nitroprusside
Table 3.13 shows that giving nitroglycerin to a patient decreases BP in 816 out of 1234,
increases CO in 245 out of 405, increases HR in 799 out of 1407, and decreases LAP in 497
out of 822 patients. However, a look at Table 3.13 shows that removing nitroglycerin also
decreases BP and LAP in a majority of patients, which lead us to think that nitroglycerin
does not have any effects on BP, and that the effects we are observing are caused by other
factors. Nitroglycerin has the adverse effect on HR on a majority of patients when removed.
There is a larger difference between percentage of patients with decrease and increase in
HR when removing nitroglycerin, compared to when adding nitroglycerin. The distribution
of diseases across different changes in each parameter for adding and removing nitroglycerin
shows no difference between the 'increase' and 'decrease' patient groups (Figure 3-7).
Nitroprusside is another type of vasodilator that relaxes the blood vessels and reduces
workload on the heart. A majority of patients had a decrease in BP and LAP, and increase
in CO and HR when they are given nitroprusside (Table 3.14). However, the distribution
of diseases for the aforementioned groups of patients (left two plots in Figure 3-8 does not
show that these patients are any different from the patients belonging to the counter group
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Figure 3-7: Distribution of diseases on patients with an increase or decrease in each of the
parameters, BP, CO, HR, and LAP, when nitroglycerin has been added (+) and removed
(-). 'Increase' from E =1 and 'Decrease' from E =1 in Table 3.13.
(e.g. group with decrease in BP vs. group with increase in BP).
Notice the difference in the relative number of patients with increase and with decrease
between in Table 3.14, between adding and removing nitroprusside. Although removal
causes each parameter to change in a different direction in a majority of patients, it is a
smaller majority than when nitroprusside was added, indicating that the drug has sustained
effects over either the set 2 hour limit or the next change in drug state. Giving nitroprusside
increased CO in most patients when added while it's almost a 50-50 split when removed.
From Figure 3-8, we cannot find any differences between each pair of increase and
decrease groups on the distribution of diseases for each of the four hemodynamic parameters
when nitroprusside is given. The same ambiguity applies to the distribution of diseases for
the increase and decrease group for each parameter when nitroprusside has been removed.
Vasoconstrictor: Neosynephrine
Levophed, a brand name for neosynephrine, is entered as a separate drug from its generic
name in MIMIC II. Although levophed and neosynephrine are the same drugs, we will
present the observed drug effects separately. Table 3.15 shows the hemodynamic effects
when levophed and other non-sympathetic drugs are added and removed.
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Increase +Nitroglycerin Increase --Nitroglycerin
.
~=1
drug # of regions # of patients
type(s) Param T o tot avg=T avg= o E=T E=1 tot
+pru BP 446(75) 923(167) 1376 152 453 177 518 696
CO 125(46) 54(18) 189 95 35 100 40 146
HR 944(127) 494(92) 1499 452 200 505 229 753
LAP 182(66) 278(65) 470 90 144 102 170 275
+pru & BP 21(1) 25(3) 46 20 23 21 23 44
+1 nSS CO 1(0) 4(1) 6 0 3 1 3 5
HR 33(4) 16(1) 51 31 15 32 15 49
LAP 5(0) 12(3) 17 4 11 4 12 16
-pru BP 819(112) 545(101) 1378 401 267 441 302 748
CO 60(17) 80(22) 143 44 61 46 68 116
HR 507(70) 971(132) 1533 227 496 260 547 822
LAP 206(53) 154(44) 371 120 83 141 89 234
-pru & BP 35(7) 24(3) 59 35 24 35 24 59
-1 nSS CO 5(2) 4(3) 11 5 4 5 4 11
HR 16(2) 42(9) 60 16 42 16 42 60
LAP 22(7) 8(1) 32 22 8 22 8 32
Table 3.14: Observed drug effects when nitroprusside (pru) and other specified drugs types
were added (+) or removed (-). Number in parenthesis is the number of regions under either
T or I that have abnormal heart rhythms.
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Figure 3-8: Distribution of diseases on patients with an increase or decrease in each of the
parameters, BP, CO, HR, and LAP, when nitroprusside has been added (+) and removed
(-). 'Increase' from E =T and 'Decrease' from E =-- in Table 3.14.
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drug # of regions # of patients
type(s) Param J tot avg= T avg= E =T Jz=i tot
+1ev BP 1244(256) 706(141) 1972 539 261 583 304 897
CO 164(50) 153(42) 329 94 86 104 97 208
HR 818(183) 1340(216) 2250 347 539 401 612 1034
LAP 403(106) 311(85) 741 221 152 247 171 425
+1ev & BP 62(17) 43(12) 106 55 36 58 38 97
+1 nSS CO 8(2) 17(5) 25 8 17 8 17 25
HR 43(9) 65(18) 113 38 55 39 58 102
LAP 27(7) 20(4) 48 25 18 26 19 46
-lev BP 777(171) 1326(286) 2120 287 588 326 681 1015
CO 217(58) 184(66) 412 130 101 145 114 266
HR 1193(210) 1008(220) 2316 492 446 584 494 1108
LAP 381(95) 480(139) 909 189 264 229 293 544
-lev & BP 43(8) 74(24) 118 33 63 34 69 104
-1 nSS CO 10(5) 8(0) 19 10 7 10 7 18
HR 73(21) 49(11) 125 60 41 65 43 111
LAP 18(6) 25(5) 44 16 22 17 23 41
Table 3.15: Observed drug effects when levophed (lev) and other specified drug types were
added (+) or removed (-). Number in parenthesis is the number of regions under either T
or I that have abnormal heart rhythms.
Levophed increases BP and LAP, and decrease HR in a majority of patients when added,
with no differences in distribution on diseases between the different patient groups. The
direction of change for the above parameters reversed in the majority of patients when
levophed is removed instead, but not with a vast majority.
Whether or not a parameter increased or decreased over the region is not dependent on
the type of region (arrhythmic or non-arrhythmic); shown in the numbers in parenthesis
in Table 3.15, there is always less regions with abnormal heart rhythms than there is with
normal heart rhythms. Distribution of diseases also show no difference between the 'increase'
and 'decrease' patient groups for each parameter when levophed is added or removed.
The direct vasoconstrictor effects of neosynephrine can be easily observed from Table
3.16 where adding the drug increased BP in 1145 out of 1793 patients, and removing it
decreased BP in 1305 out of 1965 patients. There is an even split between the number of
patients with increased and decreased CO when adding neosynephrine.
However, removal of the drug caused a majority of the patients to have an increase in
CO. Neosynephrine also decreases HR and increases LAP in a majority of patients, although
Figure 3-10 shows that there are no differences in disease distribution between each pair of
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Figure 3-9: Distribution of diseases on patients with an increase or decrease in each of
parameters, BP, CO, HR, and LAP, when levophed has been added (+) and removed
'Increase' from E =T and 'Decrease' from E =1 in Table 3.15.
the
(-).
'increase' and 'decrease' group for all parameters.
Hemodynamic changes caused by levophed and neosynephrine are comparable when we
look at the direction of change for each parameter in the majority group; they both increase
BP and LAP, and decrease HR when added. But effects from levophed seem to last longer
than that from neosynephrine the drugs are removed.
The difference between the percentage of patients with an increase in LAP when levophed
was added and the percentage of patients with a decrease in LAP when removed, is much
smaller than that between the addition and removal of neosynephrine. This indicates that
it takes a longer time for parameters to reverse their directions of change when levophed is
being removed.
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drug # of regions # of patients
type(s) Param T I Itot avg=T Iavg=I E=T IE =1 tot
+neo BP 2407(660) 1500(394) 3946 1005 545 1145 639 1793
CO 315(119) 339(129) 676 208 205 229 214 457
HR 1465(420) 2619(495) 4384 543 1097 626 1232 1943
LAP 999(367) 618(200) 1678 508 288 580 333 939
+neo & BP 130(30) 97(30) 230 120 86 124 88 214
+1 nSS CO 15(3) 28(10) 43 15 26 15 26 41
HR 76(20) 156(32) 252 72 139 73 142 234
LAP 65(25) 43(17) 116 60 41 61 42 111
-neo BP 1445(375) 2622(664) 4115 547 1150 648 1305 1965
CO 437(166) 270(90) 729 290 164 306 184 498
HR 2537(462) 1679(433) 4513 1133 662 1276 766 2131
LAP 744(244) 1003(335) 1802 389 532 446 592 1055
-neo & BP 75(26) 113(27) 189 67 101 70 105 176
-1 nSS CO 29(11) 14(8) 45 28 14 28 14 43
HR 110(18) 68(21) 198 101 65 102 65 185
LAP 39(15) 51(17) 94 37 48 37 50 91
Table 3.16: Observed drug effects when neosynephrine (neo) and other specified drug types
were added (+) or removed (-). Number in parenthesis is the number of regions under either
T or I that have abnormal heart rhythms.
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Figure 3-10: Distribution of diseases on patients with an increase or decrease in each of the
parameters, BP, CO, HR, and LAP, when neosynephrine has been added (+) and removed
(-). 'Increase' from E =T and 'Decrease' from E =1 in Table 3.16.
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Chapter 4
Discussions
There are two questions that we are trying to answer in this thesis: how are the hemody-
namic parameters related (BP vs. HR and LAP vs. CO) for the patients admitted to the
ICU, and how beta-blockers, vasodilators, and venodilators change a parameter after they
are added or removed from the ICU patients?
The last chapter presented the results in the form of correlations on each of the two
hemodynamic relations, and a distribution of diseases for patients with similar reaction to
drugs. This chapter will discuss why the results turned out the way they are and what
improvements can be made.
4.1 Hemodynamic Relations
4.1.1 Comparison of State-based Classification and Multi-Segment Lin-
ear Regression on Blood Pressure and Heart Rate
Results presented in Section 3.1.1 using state-based classification showed that non-arrhythmic
patients have better correlated BP and HR than arrhythmic patients most of the time,
whether with classification using only sympathetic state or in addition to ABP range. This
confirms our assumption that without the interference from arrhythmia [4], it is easier to
observe the interaction between BP and HR using correlations coefficients.
In addition, having classified the data using the number of sympathetic drugs and ABP
range gives better correlations than not classifying. Just as we believed that we can see
better correlations in non-sympathetic regions when no drugs are acting on the autonomic
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nervous system, it is easier to predict what will happen to HR with a change in BP in non-
sympathetic than sympathetic regions in non-arrhythmic patients (vice versa for arrhythmic
patients).
Despite the above observations, we cannot ignore the fact that all the correlations shown
in Section 3.1.1 are in the low positive range. The results indicated that BP and HR change
in the same direction more often than they do in the opposite direction, but not by much.
One reason for the low correlations is the phase shift between BP and HR fluctuations
discussed.
Let's say the baroreflex is modeled in a feedback system, with change in BP as the
input and magnitude of change in RR interval as the output, where RR interval is defined
as the time duration between two consecutive R waves of the ECG. Study showed that, at
different controlled breathing rates, there is a phase shift between when BP changes and
when baroreflex responds through changes in HR [8]. Variability of phase shift also depends
on the disease state (patients with implanted cardioverter-defibrillator have unstable phase
control), but not on age. The possibility of phase shifts have a big impact on our results;
we have assumed a 0-phase shift between a change in BP and the corresponding change in
HR through sympathetic stimulation because the nature of our data source (taken at 15
minute intervals) does not allow shifts that take place within 15 minutes.
Furthermore, the paper showed that the amount of how much HR can change (gain)
in response to a change in BP is greater in younger subjects than older subjects. Even
though we have eliminated other influences on sympathetic stimulation, such as sympathetic
drugs and cardiomyopathy, we did not take into consideration the age of each patient; the
correlation on BP and HR could be more apparent in younger than older subjects, and thus
the low correlations we have for normalizing correlation in a group of patients with different
ages.
Problems with phase shifts and variability in gain depending on the patient's state
applies to both the state-based classification method and multi-segment linear regression,
which accounts for the low correlations obtained using either method. We can certainly
improve the correlations by incorporating a patient's age and the phase shift into account
when examining the relation between BP and HR.
The results obtained using multi-segment linear regression on BP (Section 3.2.1) have
shown that increasing the number of segments increases both the percentage of patients
72
with higher correlations and the amount by which the correlations increase on average.
This leads us to think that the more segments assigned to a hospital stay (shorter average
time intervals), the higher the correlations (either towards 1 or -1). We made the assumption
that by having shorter time intervals we can better define the hemodynamic relations, by
finding a balance between a consistent hemodynamic relation within a time interval and
bounding each time interval with state changes that matter.
Although state-based classification can capture the changes caused by arrhythmia, sym-
pathetic drugs, and ABP range, it might not be enough to capture all the changes that
influence the hemodynamic relations. For example, voluntary cardio-respiratory synchro-
nization has been used to show that the heart rate speeds up during inhalation [15]. In
addition, the mood that a patient is in also plays a major role in fluctuations in BP and
HR [18]. However, since we are dealing with ICU patients who are most likely to be given
drugs like profolol to calm them down, we do not consider mood as one of the state changes
that we need to capture.
By using multi-segment linear regression, we had hoped to bound time segments with
other factors that play a role in defining the relationship between BP and HR, in addition
to smoothing out noise with enough valid data. In another words, if we had defined every
change in BP as one segment, then we would have included a lot of noise in our source data.
We saw improvement in correlations by decreasing the time interval used in multi-segment
linear regression, but the results did not prove to be much better than the ones obtained
using state-based classification.
Multi-segment linear regression uses no classification and treats every patient the same.
It might be possible to better define the relations between BP and HR if we were to consol-
idate the two methods. In addition to classifying patients using their disease and SS states,
we can run linear regression on each of those regions (sympathetic or non-sympathetic) to
capture other state changes that might have altered the relation between BP and HR.
4.1.2 Comparison of State-based Classification and Multi-Segment Lin-
ear Regression on Left Atrial Pressure and Cardiac Output
By using state-based classification on LAP, we showed that for ICU patients, LAP and
CO start to move in the same direction more often as LAP increases towards 25 at the
same time they become less correlated (Section 3.1.2). This agrees with the Frank-Starling
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mechanism since CO is incapable of continuing its increase as LAP increases towards the
plateau in the Frank-Starling curve (become less correlated). However, when LAP goes over
25, the two parameters become more correlated again, which is not clearly explained by the
Frank-Starling curve. One explanation for the improvement in correlations at the end is
the idea of a threshold at which both CO and LAP stop increasing and can only decrease.
Multi-segment linear regression does not show how CO and LAP are correlated in rela-
tion to the Frank-Starling curve, but only how the correlations are affected by the length
of time intervals. Assigning more segments to a hospital stay proved to be successful in
increasing the amount of improvement in correlations, but not in the percentage of patients
with more significant correlations (a large majority still made no improvements). Further-
more, there seems to be a threshold at which shorter time intervals can only generate more
noise, at bval=10. Thus, defining a segment between each pair of consecutive entries is not
optimal in capturing state changes that actually change hemodynamic relations while filter-
ing out noise. What this means in terms of defining regions with consistent and significant
hemodynamic relations is that, we are more likely to capture all the state changes during
a patient's hospital stay with a small bval. But at the same time, bval has to stay high
enough to minimize the variance for each fitted line.
The normalized correlations on CO and LAP obtained using these two methods have
stayed in the low positive range. However, there are patients in each group who showed
significant correlations (whether close to -1 or 1) under the constraints we specified in
state-based classification and the number of segments assigned using multi-segment linear
regression. However, since a majority of patients still have low correlations on CO and LAP,
the average correlations stayed low. Thus, closer looks at these patients could be useful in
assimilating patients across different groups and possibly provide insights into what makes
a patient different from the others.
4.2 Observed Drug Effects in Comparison with Literature
4.2.1 Beta Blockers: Dobutamine and Dopamine
Correlations presented in Table 3.11 show that a majority of the patients had an increase
in CO when they are given dobutamine. In the left two plots in Figure 3-5, most of the
patients with an increase in CO has some form of heart disease (ICD9 420-429), which
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agrees with other research on effects of intravenous dobutamine [1]. It is not clear, however,
whether CO increase or decrease in patients without congestive heart failure (CHF). Our
results showed that 80% of the patients with a decrease in CO also have some form of heart
disease. Look at the bottom half of Table 3.11 when dobutamine has been removed, CO
decreased in a majority of patients, which confirms that CO increases when dobutamine
has been added.
Study has shown that dobutamine does not significantly change the mean pulmonary
arterial pressure and mean arterial pressure in CHF patients [1]. Comparing the results for
LAP and BP in Table 3.11, there is no significant difference in the two parameters between
adding and removing dobutamine, and neither can differences be observed from Figure 3-5
in the different patient groups.
Furthermore, HR increased and decreased in most of the patients when dobutamine
has been added and removed, respectively [3]. However, our results demonstrated that
whether a parameter increased or decreased did not make a difference in the distribution
of diseases attributed to patients in the group. What we had hoped to find, for example,
is a big contrast in the number of patients with ICD9 code between 420 and 429 when the
parameter increased and when it decreased (e.g. 90% has heart failure when BP increased
and only 20% has heart failure when BP decreased).
Dopamine is another beta-blocker that has been used in ICU and studied extensively.
Literature showed that dopamine increases CO, PCWP, and HR in patients with severe
left ventricular failure (ICD9 428) [12]. Our results shown in Table 3.12 agree with the
increase in CO and HR when dopamine has been added. The patient demographics on the
groups with increase and decrease in CO when dopamine has been removed showed that a
majority of patients have 'other forms of heart disease' (ICD9 428) both when CO increased
and when CO decreased.
The increase in PCWP (from literature), which we had used to estimate LAP, does not
exactly agree with our results from the addition of dopamine; LAP increased and decreased
almost for an even number of patients both when dopamine is given or removed, even when
a majority of patients in all 4 patients groups (increase and decrease when dopamine is
given, or removed) have some form of heart disease.
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4.2.2 Vasodilators: Nitroglycerin and Nitroprusside
From the results we have obtained, giving patients nitroglycerin decreases BP in 8156 out of
1234 patients, increases CO in 245 out of 405, increases HR in 799 out of 1407, and decreases
LAP in 497 out of 1407 patients (Table 3.13). Figure 3-7 shows that the only difference
between patients with increase and decrease in LAP is that there are more patients with
ischemic heart disease (ICD9 410-414) in the former than in the latter group. Differences
in the disease distributions in groups with increase and decrease in the other parameters
could not be observed.
Removing nitroglycerin gave almost the same results as adding nitroglycerin as shown
in Table 3.13, decreasing both BP and HR, leading us to think that either nitroglycerin does
not have any effects on these two parameters, or that it takes more than 2 hours for the
effects to diminish. But it has been shown that ordinary peripheral artery BP measurements
are inadequate in showing the vasodilation effects of nitroglycerin [20].
Thus, since we cannot ensure that our BP measurements are not measured peripherally,
BP should not be used in assessing the hemodynamic effects of nitroglycerin. On the
other hand, other studies have shown that intravenous nitroglycerin decreases both BP and
PCWP [16], which is what we have observed in Table 3.13. The same study, however, also
showed that nitroglycerin decreases HR in patients with severe left ventricular failure [12],
disagreeing with our results.
Nitroprusside decreases BP in 518 out of 696 patients, increases CO in 100 out of 146
patients and HR in 505 out of 753 patients, and decreases LAP in 170 out of 275 patients
(Table 3.14, with the adverse effects on the majority when nitroprusside is removed. Study
conducted by Bixler showed that nitroprusside is effective in lowering BP in hypertensive
patients without significantly changing CO, while improving CO in patients with left ven-
tricular failure with normal BP [2].
The effect of nitroprusside is twofold; improving the abnormal parameter between BP
and CO while keeping the normal parameter unaffected. Our results shown in Figure 3-8
(when nitroprusside has been added) also shows a prevalence of hypertensive disease (ICD9
410-414) in the patient group with a decrease in BP, while other heart diseases, including left
ventricular failure (ICD9 428), dominate in the increase group for CO when nitroprusside
was given. The relative disease distribution for BP applies to HR (ICD9 401-405 dominates),
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while the distribution of CO is similar to that of LAP's (ICD9 420-429).
4.2.3 Vasoconstrictor: Neosynephrine
As shown in Tables 3.15 and 3.16, both levophed and neosynephrine increases BP and
LAP, and decreases HR in most patients when added. And removing either drug reverses
the drug effects by decreasing both BP and LAP, and increasing HR. But the number of
patients with an increase and decrease in CO when drug was added stay pretty evenly
with no observable difference in disease distribution. No differences can be observed either
in the disease distribution between the decrease and increase patient group for BP, HR,
and LAP. The increase in BP and LAP agrees with what other research has found, but
not the decrease in HR [5]. In the experiments conducted by Cohn [5], all of the studied
hemodynamic parameters had a mean increase over a total of 24 patients.
Other studies have shown, however, that HR decreases significantly as we have found [9].
But the study was conducted on adult dogs, the cardiovascular system of which is certainly
different from that of patients in the ICU that we have examined.
4.2.4 Patient Demographics
In this thesis, we looked at the percentage of patients with each category of disease listed in
Table 3.10. Each of these categories consist of a set of more specific diseases. For example,
'chronic rheumatic heart disease' includes everything from chronic rheumatic pericarditis to
diseases of the aortic and mitral valve. And 'other forms of heart disease' covers even a larger
set, from diseases of pericardium to endocardium, cardiomyopathy, to heart failure. One
drawback of assigning diseases into the same category is not knowing the specific diseases
attributed to each patient, as shown in the figures in the last chapter on the distribution of
diseases in each group of patients.
One improvement that can be made is having smaller categories, which will allow us to
study the effects specific diseases have on how patients react to the same drugs. Take for
example, a majority of patients have 'other forms of heart disease' in both patient groups
(increase and decrease). If we were to look at smaller categories, we might find out that in
the group with an increase, 100% of the patients have cardiomyopathy, while none of the
patients in the group with a decrease have cardiomyopathy (maybe 90% have heart failure
and the other 10% have diseases of the pericardium).
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Often it is not a single disease that caused a patient to have a different reaction to the
same drug, but a combination of diseases. Instead of looking at the number of patients in
each category (Table 3.10), or with each specific disease as mentioned before, finding out the
distribution of each combination of diseases can provide an insight into what combinations
give certain kinds of reactions. For example, giving dobutamine to a hypertensive patient
might not bring down BP, nor will it bring down BP in a CHF patient. However, it might
decrease BP in a patient with both hypertension and CHF.
4.3 Biological Data
Inaccurate data can be the result of human and computer error, or simply the inability to
record everything that happens to a patient. For example, the two inconsistent validity
checkers on obtaining the mean arterial pressure mentioned in Section 2.1.1 is a result
of a combination of human and computer error. Or inaccuracy caused by fluctuations in
BP due to a change in the patient's position (i.e. from supine to upright position), or
from estimating left atrial pressure from pulmonary wedge pressure or diastolic pulmonary
arterial pressure, or from the relative position of the arm to the heart when measuring BP.
In addition, there exist many methods for measuring the same hemodynamic parameter.
One example is cardiac output. Kothari showed in his paper that CO measurements differ
with various methods, even for the same patient [10]. The difference in measurements under
the same conditions for the same patient does not have a big impact on our results unless
various methods have been used on the same patient at different times during his hospital
stay, or unless we are studying across patients. Once we start to make comparisons between
patients, it is best to ensure a standard in taking measurements across patients.
Moreover, our results suffered from a lack of data on similar patients and similar time
regions. For example, there are no available CO measurements over regions with the addi-
tion of dobutamine and a non-sympathetic drug (Table 3.11), or that LAP measurements
during the removal of dopamine and a non-sympathetic drug are only available from 8
patients (Table 3.12).
There are numerous factors that could have caused inaccuracy in the data source. Unless
we can record, for example, when a patient changes position, we cannot avoid the inaccuracy
caused by fluctuations in BP due to the change in position. Or unless we can supervise every
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patient for the whole hospital stay and take measurements according to a standard we set
for our purposes, we cannot be sure of the position of the arm relative to the heart when a
measurement of BP is taken. Standardized methods of measuring hemodynamic parameters,
in addition to identifying noise in the data, are essential for studying hemodynamic relations
in ICU patients.
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